




Belgian Cancer Registry

CANCER FACT SHEET 2022

LUNG CANCER

ICD-10 C34



CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ($=200 \times 1.05$) and 255/100,000 over 5 years ($=200 \times (1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standardised Population (ESP): standardisation is needed to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is needed to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. The stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. For lung cancer, stage IV means the cancer has spread to other organs. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

Net survival: often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc.

95% CI: 95% confidence intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

SCLC: Small cell lung cancer.

NSCLC: Non-small cell lung cancer.

- **SCC:** Squamous cell carcinoma, a type of non-small cell lung cancer.
- **ADC:** Adenocarcinoma, a type of non-small cell lung cancer.
- **LCC:** Large cell undifferentiated carcinoma, a type of non-small cell lung cancer.



1. Cancer Incidence.....	5
1.1. Lung Cancer Incidence: By region.....	5
1.1.1. Lung Cancer Incidence: Region, by sex, the number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022.....	5
1.2. Lung Cancer Incidence: By tumour stage.....	7
1.2.2. Lung Cancer Incidence: Clinical stage, by sex and age group, the number of new diagnoses, crude and age-standardised incidence rates, 2022	7
1.2.3. Lung Cancer Incidence: Pathological stage, by sex and age group, the number of new diagnoses, crude and age-standardised incidence rates, 2022.....	8
1.2.4. Lung Cancer Incidence: Stage, by sex and age group, the number of new diagnoses, crude and age-standardised incidence rates, 2022.....	8
1.2.5. Lung Cancer Incidence: Stage for histological types of lung cancer, by sex and age group, the number of new diagnoses, crude and age-standardised incidence rates, 2022	9
2. Cancer Incidence Trends.....	11
2.1. Lung Cancer Incidence Trends: By region	11
2.1.1. Lung Cancer Incidence Trends: Males, by region, the number of new diagnoses, crude and age-standardised incidence rates, over the 2018-2022 period, including average annual percentage change from 2004 onwards.....	11
2.1.2. Lung Cancer Incidence Trends: Females, by region, the number of new diagnoses, crude and age-standardised incidence rates, over the 2018-2022 period, including average annual percentage change from 2004 onwards.....	13
2.2. Lung Cancer Incidence Trends: By tumour stage	15
2.2.3. Lung Cancer Incidence Trends: Stage, the number of new diagnoses, crude and age-standardised incidence rates, over the 2018-2022 period, including average annual percentage change from 2004 onwards	15
2.3. Lung Cancer Incidence Trends: By age group	17
2.3.4. Lung Cancer Incidence Trends: Males, by age group, the number of new diagnoses, crude and age-standardised incidence rates, over the 2004-2022 period, including average annual percentage change	17
2.3.5. Lung Cancer Incidence Trends: Females, by age group, the number of new diagnoses, crude and age-standardised incidence rates, over the 2004-2022 period, including average annual percentage change	18
3. Cancer Prevalence	19
3.1. Lung Cancer Prevalence: By region	19
3.1.1. Lung Cancer Prevalence: Region, by sex, the number of prevalent cases, crude and age-standardised prevalence rates.....	19
4. Cancer Survival	20
4.1. Lung Cancer Survival: By region	20
4.1.1. Lung Cancer Survival: Region, by sex and age group, the number at risk and net survival probabilities, 2013-2022.....	20
4.2. Lung Cancer Survival: By stage for the histological types of lung cancer.....	22
4.2.2. Lung Cancer Survival: Clinical stage for the histological types of lung cancer, by sex, the number at risk and net survival probabilities, 2013-2022	22

4.2.3. Lung Cancer Survival: Pathological stage for the histological types of lung cancer, by sex, the number at risk and net survival probabilities, 2013-2022	26
4.2.4. Lung Cancer Survival: Stage for the histological types of lung cancer, by sex, the number at risk and net survival probabilities, 2013-2022	30
5. Cancer Survival Trends.....	34
5.1. Lung Cancer Survival Trends: By stage	34
5.1.1. Lung Cancer Survival Trends: Stage, by sex, the number at risk and net survival probabilities over the 2008-2022 period.....	34
6. Cancer Mortality	36
6.1. Lung Cancer Mortality: By region, 2021	36
6.1.1. Lung Cancer Mortality*: Region, by sex, the number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021	36
7. Cancer Mortality Trends.....	38
7.1. Lung Cancer Mortality Trends: By Region	38
7.1.1. Lung Cancer Mortality* Trends: Males, by region, the number of cancer deaths, crude and age-standardised mortality rates over the 2004-2021 period, including average annual percentage change.....	38
7.1.2. Lung Cancer Mortality* Trends: Females, by region, the number of cancer deaths, crude and age-standardised mortality rates over the 2004-2021 period, including average annual percentage change.....	40

1. CANCER INCIDENCE



1.1. Lung Cancer Incidence: By region

1.1.1. Lung Cancer Incidence: Region, by sex, the number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Males																						
Belgium	1	0	0	0	0	0	5	16	43	73	194	396	729	1,055	1,135	975	642	317	91	5	5,677	106.1
	[0.3]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.3]	[4.3]	[11.3]	[19.5]	[49.0]	[98.0]	[197.5]	[337.7]	[429.9]	[512.5]	[507.1]	[404.1]	[303.1]	[85.5]	[99.4]	(103.3; 108.9)
Brussels	0	0	0	0	0	0	0	1	3	6	28	46	63	55	64	54	25	19	4	1	369	95.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.1]	[6.5]	[13.8]	[69.3]	[132.6]	[225.3]	[259.8]	[387.4]	[443.6]	[309.6]	[373.5]	[184.5]	[187.6]	[61.5]	(85.2; 105.1)
Flanders	0	0	0	0	0	0	3	6	20	32	84	185	376	598	660	629	433	229	62	4	3,321	99.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.4]	[2.9]	[9.2]	[15.2]	[36.3]	[75.7]	[167.2]	[311.4]	[408.3]	[509.5]	[518.2]	[436.5]	[311.1]	[105.8]	[100.1]	(96.2; 103.0)
Wallonia	1	0	0	0	0	0	2	9	20	35	82	165	290	402	411	292	184	69	25	0	1,987	120.4
	[1.1]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.7]	[7.8]	[17.3]	[29.0]	[65.9]	[131.9]	[249.6]	[405.0]	[478.9]	[534.7]	[526.3]	[330.3]	[315.2]	[0.0]	[110.9]	(115.0; 125.7)
Females																						
Belgium	0	0	0	1	1	2	9	20	31	86	183	352	558	758	719	516	315	126	50	6	3,733	60.8
	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.6]	[2.3]	[5.4]	[8.2]	[23.4]	[47.3]	[88.3]	[148.1]	[227.9]	[243.5]	[223.3]	[176.8]	[93.6]	[72.1]	[29.2]	[63.5]	(58.9; 62.8)
Brussels	0	0	0	0	0	0	2	2	4	6	13	16	28	46	48	40	25	12	7	1	250	51.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[3.8]	[4.2]	[8.9]	[14.9]	[34.9]	[47.4]	[94.1]	[184.7]	[225.1]	[232.0]	[191.9]	[119.3]	[121.3]	[48.5]	[40.2]	(45.3; 58.2)
Flanders	0	0	0	1	0	2	5	16	15	38	85	198	299	431	382	287	194	73	33	3	2,062	55.9

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Wallonia	[0.0]	[0.0]	[0.0]	[0.6]	[0.0]	[1.0]	[2.4]	[7.6]	[6.9]	[18.4]	[37.7]	[83.1]	[133.2]	[218.0]	[220.0]	[200.7]	[173.2]	[85.8]	[77.5]	[24.8]	[61.0]	(53.5; 58.3)
	0	0	0	0	1	0	2	2	12	42	85	138	231	281	289	189	96	41	10	2	1,421	72.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[1.7]	[1.7]	[10.3]	[35.0]	[68.4]	[108.7]	[188.7]	[255.5]	[288.2]	[266.6]	[180.5]	[103.8]	[47.5]	[31.4]	[76.0]	(68.5; 76.0)

1.2. Lung Cancer Incidence: By tumour stage

1.2.2. Lung Cancer Incidence: Clinical stage, by sex and age group, the number of new diagnoses, crude and age-standardised incidence rates, 2022

stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	141 [4.2]	690 [73.0]	474 [109.9]	1,305 [22.9]	24.5 (23.1; 25.8)	186 [5.6]	541 [53.9]	259 [40.9]	986 [16.8]	16.2 (15.2; 17.2)
II	37 [1.1]	199 [21.0]	170 [39.4]	406 [7.1]	7.7 (6.9; 8.4)	38 [1.2]	128 [12.7]	84 [13.3]	250 [4.3]	4.1 (3.6; 4.6)
III	137 [4.1]	553 [58.5]	375 [87.0]	1,065 [18.7]	19.8 (18.6; 21.0)	100 [3.0]	343 [34.1]	162 [25.6]	605 [10.3]	9.9 (9.1; 10.7)
IV	376 [11.2]	1,328 [140.5]	888 [206.0]	2,592 [45.4]	48.3 (46.4; 50.1)	324 [9.8]	916 [91.2]	444 [70.0]	1,684 [28.7]	27.3 (26.0; 28.6)
X/NA	36 [1.1]	149 [15.8]	123 [28.5]	309 [5.4]	5.8 (5.2; 6.5)	37 [1.1]	107 [10.7]	64 [10.1]	208 [3.5]	3.4 (2.9; 3.9)

1.2.3. Lung Cancer Incidence: Pathological stage, by sex and age group, the number of new diagnoses, crude and age-standardised incidence rates, 2022

stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	105 [3.1]	387 [40.9]	135 [31.3]	627 [11.0]	11.4 (10.5; 12.3)	156 [4.7]	325 [32.4]	80 [12.6]	561 [9.5]	9.4 (8.6; 10.2)
II	29 [0.9]	138 [14.6]	57 [13.2]	224 [3.9]	4.1 (3.6; 4.6)	36 [1.1]	104 [10.4]	27 [4.3]	167 [2.8]	2.8 (2.4; 3.2)
III	24 [0.7]	76 [8.0]	42 [9.7]	142 [2.5]	2.6 (2.2; 3.1)	26 [0.8]	53 [5.3]	16 [2.5]	95 [1.6]	1.6 (1.3; 1.9)
IV	64 [1.9]	185 [19.6]	125 [29.0]	374 [6.6]	7.0 (6.2; 7.7)	52 [1.6]	123 [12.2]	53 [8.4]	228 [3.9]	3.7 (3.2; 4.2)
X/NA	505 [15.1]	2,133 [225.6]	1,671 [387.6]	4,310 [75.5]	81.0 (78.6; 83.4)	415 [12.6]	1,430 [142.4]	837 [132.0]	2,682 [45.7]	43.4 (41.7; 45.0)

1.2.4. Lung Cancer Incidence: Stage, by sex and age group, the number of new diagnoses, crude and age-standardised incidence rates, 2022

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	140 [4.2]	675 [71.4]	473 [109.7]	1,288 [22.6]	24.2 (22.8; 25.5)	183 [5.6]	530 [52.8]	257 [40.5]	970 [16.5]	15.9 (14.9; 16.9)
II	43 [1.3]	232 [24.5]	168 [39.0]	443 [7.8]	8.3 (7.5; 9.1)	46 [1.4]	154 [15.3]	92 [14.5]	292 [5.0]	4.8 (4.2; 5.3)
III	137 [4.1]	564 [59.7]	391 [90.7]	1,092 [19.1]	20.4 (19.2; 21.6)	108 [3.3]	356 [35.4]	169 [26.7]	633 [10.8]	10.3 (9.5; 11.2)
IV	381 [11.4]	1,342 [141.9]	896 [207.8]	2,619 [45.9]	48.8 (46.9; 50.6)	324 [9.8]	922 [91.8]	449 [70.8]	1,695 [28.9]	27.5 (26.2; 28.8)
X/NA	26 [0.8]	106 [11.2]	102 [23.7]	235 [4.1]	4.5 (3.9; 5.1)	24 [0.7]	73 [7.3]	46 [7.3]	143 [2.4]	2.3 (1.9; 2.7)

1.2.5. Lung Cancer Incidence: Stage for histological types of lung cancer, by sex and age group, the number of new diagnoses, crude and age-standardised incidence rates, 2022

Histological types	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
SCLC	I	5 [0.1]	16 [1.7]	7 [1.6]	28 [0.5]	0.5 (0.3; 0.7)	1 [0.0]	10 [1.0]	7 [1.1]	18 [0.3]	0.3 (0.2; 0.4)
	II	2 [0.1]	7 [0.7]	6 [1.4]	15 [0.3]	0.3 (0.1; 0.4)	6 [0.2]	16 [1.6]	4 [0.6]	26 [0.4]	0.4 (0.3; 0.6)
	III	16 [0.5]	87 [9.2]	40 [9.3]	143 [2.5]	2.6 (2.2; 3.0)	22 [0.7]	69 [6.9]	27 [4.3]	118 [2.0]	1.9 (1.6; 2.3)
	IV	64 [1.9]	293 [31.0]	142 [32.9]	499 [8.7]	9.2 (8.4; 10.0)	53 [1.6]	207 [20.6]	66 [10.4]	326 [5.5]	5.4 (4.8; 5.9)
	X/NA	3 [0.1]	13 [1.4]	14 [3.2]	30 [0.5]	0.6 (0.4; 0.8)	2 [0.1]	14 [1.4]	8 [1.3]	24 [0.4]	0.4 (0.2; 0.5)
NSCLC	I	115 [3.4]	515 [54.5]	281 [65.2]	911 [16.0]	16.9 (15.8; 18.0)	169 [5.1]	410 [40.8]	161 [25.4]	740 [12.6]	12.3 (11.4; 13.2)
	II	39 [1.2]	207 [21.9]	126 [29.2]	372 [6.5]	6.9 (6.2; 7.6)	39 [1.2]	127 [12.6]	69 [10.9]	235 [4.0]	3.9 (3.4; 4.4)
	III	119 [3.6]	457 [48.3]	297 [68.9]	873 [15.3]	16.2 (15.2; 17.3)	85 [2.6]	277 [27.6]	121 [19.1]	483 [8.2]	7.9 (7.2; 8.6)
	IV	310 [9.3]	1,005 [106.3]	615 [142.6]	1,930 [33.8]	35.8 (34.2; 37.4)	268 [8.1]	680 [67.7]	330 [52.1]	1,278 [21.8]	20.8 (19.7; 22.0)
	X/NA	20 [0.6]	77 [8.1]	72 [16.7]	169 [3.0]	3.2 (2.7; 3.7)	15 [0.5]	45 [4.5]	34 [5.4]	94 [1.6]	1.5 (1.2; 1.8)
SCC	I	17 [0.5]	174 [18.4]	110 [25.5]	301 [5.3]	5.7 (5.0; 6.3)	6 [0.2]	71 [7.1]	40 [6.3]	117 [2.0]	1.9 (1.6; 2.3)
	II	12 [0.4]	94 [9.9]	64 [14.8]	170 [3.0]	3.2 (2.7; 3.7)	6 [0.2]	34 [3.4]	25 [3.9]	65 [1.1]	1.1 (0.8; 1.3)
	III	49 [1.5]	234 [24.7]	175 [40.6]	458 [8.0]	8.6 (7.8; 9.4)	15 [0.5]	88 [8.8]	42 [6.6]	145 [2.5]	2.4 (2.0; 2.8)
	IV	44 [1.3]	280 [29.6]	171 [39.7]	495 [8.7]	9.2 (8.4; 10.0)	13 [0.4]	92 [9.2]	57 [9.0]	162 [2.8]	2.6 (2.2; 3.0)
	X/NA	3 [0.1]	28 [3.0]	33 [7.7]	64 [1.1]	1.2 (0.9; 1.5)	0 [0.0]	9 [0.9]	8 [1.3]	17 [0.3]	0.3 (0.1; 0.4)
ADC	I	87 [2.6]	305 [32.3]	151 [35.0]	543 [9.5]	10.0 (9.1; 10.8)	126 [3.8]	287 [28.6]	96 [15.1]	509 [8.7]	8.4 (7.7; 9.2)
	II	23 [0.7]	91 [9.6]	50 [11.6]	164 [2.9]	3.0 (2.6; 3.5)	23 [0.7]	73 [7.3]	34 [5.4]	130 [2.2]	2.1 (1.8; 2.5)
	III	61 [1.8]	177 [18.7]	101 [23.4]	339 [5.9]	6.3 (5.6; 6.9)	61 [1.9]	165 [16.4]	67 [10.6]	293 [5.0]	4.8 (4.3; 5.4)
	IV	236 [7.0]	618 [65.4]	382 [88.6]	1,236 [21.7]	22.9 (21.6; 24.2)	233 [7.1]	520 [51.8]	245 [38.7]	998 [17.0]	16.3 (15.3; 17.3)
	X/NA	13 [0.4]	40 [4.2]	31 [7.2]	84 [1.5]	1.6 (1.2; 1.9)	11 [0.3]	30 [3.0]	24 [3.8]	65 [1.1]	1.0 (0.8; 1.3)
LCC	I	0 [0.0]	3 [0.3]	2 [0.5]	5 [0.1]	0.1 (0.0; 0.2)	2 [0.1]	2 [0.2]	0 [0.0]	4 [0.1]	0.1 (0.0; 0.1)

Histological types	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
	II	0 [0.0]	2 [0.2]	5 [1.2]	7 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	2 [0.2]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)
	III	4 [0.1]	9 [1.0]	2 [0.5]	15 [0.3]	0.3 (0.1; 0.4)	2 [0.1]	6 [0.6]	1 [0.2]	9 [0.2]	0.2 (0.1; 0.2)
	IV	5 [0.1]	35 [3.7]	21 [4.9]	61 [1.1]	1.1 (0.9; 1.4)	4 [0.1]	13 [1.3]	11 [1.7]	28 [0.5]	0.4 (0.3; 0.6)
	X/NA	2 [0.1]	2 [0.2]	2 [0.5]	6 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
Other NSCLC	I	11 [0.3]	33 [3.5]	18 [4.2]	62 [1.1]	1.2 (0.9; 1.4)	35 [1.1]	50 [5.0]	25 [3.9]	110 [1.9]	1.8 (1.5; 2.2)
	II	4 [0.1]	20 [2.1]	7 [1.6]	31 [0.5]	0.6 (0.4; 0.8)	10 [0.3]	18 [1.8]	10 [1.6]	38 [0.6]	0.6 (0.4; 0.8)
	III	5 [0.1]	37 [3.9]	19 [4.4]	61 [1.1]	1.1 (0.8; 1.4)	7 [0.2]	18 [1.8]	11 [1.7]	36 [0.6]	0.6 (0.4; 0.8)
	IV	25 [0.7]	72 [7.6]	41 [9.5]	138 [2.4]	2.5 (2.1; 3.0)	18 [0.5]	55 [5.5]	17 [2.7]	90 [1.5]	1.5 (1.2; 1.8)
	X/NA	2 [0.1]	7 [0.7]	6 [1.4]	15 [0.3]	0.3 (0.1; 0.4)	4 [0.1]	6 [0.6]	2 [0.3]	12 [0.2]	0.2 (0.1; 0.3)
Other	I	20 [0.6]	144 [15.2]	185 [42.9]	349 [6.1]	6.8 (6.0; 7.5)	13 [0.4]	110 [11.0]	89 [14.0]	212 [3.6]	3.3 (2.9; 3.8)
	II	2 [0.1]	18 [1.9]	36 [8.3]	56 [1.0]	1.1 (0.8; 1.4)	1 [0.0]	11 [1.1]	19 [3.0]	31 [0.5]	0.5 (0.3; 0.6)
	III	2 [0.1]	20 [2.1]	54 [12.5]	76 [1.3]	1.5 (1.2; 1.9)	1 [0.0]	10 [1.0]	21 [3.3]	32 [0.5]	0.5 (0.3; 0.7)
	IV	7 [0.2]	44 [4.7]	139 [32.2]	190 [3.3]	3.8 (3.3; 4.4)	3 [0.1]	35 [3.5]	53 [8.4]	91 [1.5]	1.3 (1.0; 1.6)
	X/NA	3 [0.1]	16 [1.7]	16 [3.7]	36 [0.6]	0.7 (0.5; 0.9)	7 [0.2]	14 [1.4]	4 [0.6]	25 [0.4]	0.4 (0.3; 0.6)

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
CR	112.1	111.1	105.5	108.3	108.7	111.1	107.6	111.4	115.5	110.6	113.1	112.7	105.4	112.1	109.6	111.6	107.5	107.5	110.9			
ESR2013	142.0	143.2	135.0	135.5	135.2	135.9	132.3	137.9	140.7	132.1	134.7	134.0	122.9	129.7	124.2	125.0	118.9	118.6	120.4	-1.0 (-1.2; -0.7)	2004-2022	
																				-0.5 (-0.9; 0.0)	2004-2014	
																					-1.5 (-2.1; -1.0)	2015-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Lung Cancer Incidence Trends: Females, by region, the number of new diagnoses, crude and age-standardised incidence rates, over the 2018-2022 period, including average annual percentage change from 2004 onwards

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period		
Belgium	N	1,554	1,592	1,704	1,879	1,814	2,080	2,248	2,347	2,368	2,503	2,673	2,673	2,754	2,885	3,121	3,267	3,326	3,526	3,733			
	CR	29.3	29.8	31.7	34.8	33.3	37.9	40.7	42.1	42.1	44.3	47.1	46.9	48.1	50.1	54.0	56.3	57.0	60.3	63.5			
	ESR2013	30.5	31.0	32.8	35.8	34.4	39.0	41.6	43.2	42.9	45.1	47.3	46.8	48.1	49.7	53.1	55.0	55.4	58.3	60.8	3.9 (3.7; 4.2)	2004-2022	
																					5.3 (4.5; 6.1)	2004-2010	
																						3.3 (2.9; 3.6)	2011-2022
Brussels	N	185	163	189	194	170	203	211	223	221	238	222	235	227	239	258	248	241	247	250			
	CR	35.6	31.2	35.7	36.3	31.4	36.8	37.5	38.7	37.7	40.1	37.2	39.0	37.3	39.2	42.1	40.3	38.8	39.8	40.2			
	ESR2013	40.1	36.3	41.6	42.7	37.0	44.1	45.7	48.5	47.8	52.3	47.8	49.7	48.1	50.4	53.5	51.6	50.3	52.2	51.7	1.9 (1.4; 2.4)	2004-2022	
																					3.5 (2.1; 5.0)	2004-2011	
																						1.0 (0.1; 1.8)	2012-2022
Flanders	N	824	864	888	996	977	1,079	1,207	1,258	1,270	1,350	1,425	1,459	1,503	1,559	1,737	1,821	1,853	1,969	2,062			
	CR	27.0	28.2	28.8	32.1	31.3	34.3	38.1	39.4	39.5	41.8	43.9	44.7	45.9	47.3	52.4	54.7	55.3	58.6	61.0			
	ESR2013	27.6	28.4	29.0	32.1	31.3	34.1	37.5	38.9	38.5	40.7	42.2	42.9	43.8	44.8	49.5	50.9	51.5	54.1	55.9	4.2 (3.9; 4.4)	2004-2022	
																					5.1 (4.3; 5.9)	2004-2011	
																					2.8 (1.7; 4.0)	2012-2015	
																					4.0 (3.2; 4.7)	2016-2022	
Wallonia	N	545	565	627	689	667	798	830	866	877	915	1,026	979	1,024	1,087	1,126	1,198	1,232	1,310	1,421			
	CR	31.3	32.3	35.7	39.0	37.5	44.6	46.2	47.8	48.2	50.0	55.9	53.2	55.5	58.8	60.7	64.5	66.1	70.3	76.0			
	ESR2013	33.2	34.4	37.6	40.8	39.2	46.8	48.0	49.7	49.6	51.4	56.8	52.9	55.9	58.6	59.7	63.4	63.9	67.5	72.3	4.1 (3.8; 4.5)	2004-2022	
																					5.8 (4.8; 6.8)	2004-2011	
																					3.1 (2.5; 3.7)	2012-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Lung Cancer Incidence Trends: By tumour stage

2.2.3. Lung Cancer Incidence Trends: Stage, the number of new diagnoses, crude and age-standardised incidence rates, over the 2018-2022 period, including average annual percentage change from 2004 onwards

Stage	Males							Females							
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
I	N	1,046	1,199	1,125	1,216	1,288			693	760	781	934	970		
	CR	18.7	21.3	19.9	21.4	22.6			12.0	13.1	13.4	16.0	16.5		
	ESR2013	20.8	23.4	21.6	23.2	24.2	1.8 (1.3; 2.3)	2004-2022	12.0	12.9	13.0	15.6	15.9	8.4 (7.9; 8.9)	2004-2022
													11.4 (9.4; 13.3)	2004-2009	
													7.3 (6.7; 7.9)	2010-2022	
II	N	451	464	406	443	443			216	230	227	230	292		
	CR	8.1	8.2	7.2	7.8	7.8			3.7	4.0	3.9	3.9	5.0		
	ESR2013	9.0	9.1	7.9	8.4	8.3	0.9 (0.2; 1.5)	2004-2022	3.7	3.9	3.8	3.8	4.8	7.1 (5.9; 8.4)	2004-2022
						5.1 (3.6; 6.6)	2004-2013						11.7 (8.0; 15.5)	2004-2011	
						-3.2 (-4.6; -1.8)	2014-2022						4.4 (2.3; 6.5)	2012-2022	
III	N	1,259	1,144	1,094	1,109	1,092			592	620	579	606	633		
	CR	22.5	20.3	19.3	19.5	19.1			10.2	10.7	9.9	10.4	10.8		
	ESR2013	25.0	22.3	20.8	21.1	20.4	-1.1 (-1.5; -0.6)	2004-2022	10.1	10.5	9.6	10.0	10.3	4.2 (3.7; 4.8)	2004-2022
						0.6 (-0.3; 1.6)	2004-2013						6.6 (5.1; 8.1)	2004-2012	
						-2.7 (-3.7; -1.8)	2014-2022						2.4 (1.3; 3.5)	2013-2022	
IV	N	2,708	2,648	2,742	2,784	2,619			1,471	1,532	1,615	1,674	1,695		
	CR	48.4	47.0	48.4	49.0	45.9			25.5	26.4	27.7	28.6	28.9		
	ESR2013	53.9	51.6	52.6	52.9	48.8	1.6 (1.2; 1.9)	2004-2022	24.8	25.7	26.9	27.6	27.5	6.1 (5.6; 6.6)	2004-2022
						3.2 (2.5; 4.0)	2004-2014						8.2 (7.2; 9.2)	2004-2014	
						-0.5 (-1.4; 0.4)	2015-2022						3.6 (2.3; 4.8)	2015-2022	

Stage	Males							Females						
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
X/NA N	305	207	214	126	235			149	125	124	82	143		
CR	5.4	3.7	3.8	2.2	4.1			2.6	2.2	2.1	1.4	2.4		
ESR2013	6.2	4.1	4.1	2.4	4.5	-14.5 (-15.8; -13.1)	2004-2022	2.5	2.1	2.0	1.3	2.3	-10.3 (-11.7; -8.9)	2004-2022
						-10.8 (-14.2; -7.2)	2004-2012						-4.4 (-9.3; 0.9)	2004-2010
						-17.4 (-19.9; -14.8)	2013-2022						-13.1 (-15.2; -11.0)	2011-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Lung Cancer Incidence Trends: By age group

2.3.4. Lung Cancer Incidence Trends: Males, by age group, the number of new diagnoses, crude and age-standardised incidence rates, over the 2004-2022 period, including average annual percentage change

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
15-59	N	1,171	1,139	1,158	1,158	1,174	1,171	1,084	1,090	1,105	1,031	1,013	944	896	861	855	834	816	781	727		
	CR	36.7	35.5	35.9	35.8	36.1	35.8	33.0	33.0	33.3	31.0	30.5	28.4	26.9	25.8	25.6	25.0	24.4	23.4	21.7		
	ESR2013	39.7	37.7	37.7	37.4	37.7	37.3	34.1	33.8	33.8	31.3	30.4	28.0	26.3	25.2	24.9	24.2	23.6	22.6	21.1	-3.3 (-3.5; -3.1)	2004-2022
60-74	N	2,707	2,646	2,547	2,654	2,572	2,579	2,659	2,663	2,779	2,735	2,815	2,862	2,732	2,894	2,974	2,941	2,909	2,896	2,919		
	CR	397.8	386.3	370.8	379.2	360.9	354.7	358.7	352.3	361.2	349.1	353.3	352.2	328.1	337.8	338.2	327.4	317.3	309.9	308.7		
	ESR2013	395.5	385.0	370.7	382.2	367.0	362.5	367.6	362.8	371.0	359.5	363.5	361.7	338.2	346.4	344.9	332.9	322.9	315.0	314.7	-1.2 (-1.3; -1.0)	2004-2022
75+	N	1,632	1,627	1,663	1,698	1,734	1,770	1,920	1,906	1,942	1,966	1,981	1,937	1,845	1,876	1,940	1,887	1,856	1,999	2,030		
	CR	556.7	537.5	529.5	521.2	514.9	512.2	542.3	527.7	526.1	522.8	516.6	494.8	467.4	475.2	488.4	467.0	448.8	480.4	470.8		
	ESR2013	519.5	510.2	500.6	485.6	481.4	482.2	523.0	510.9	508.9	506.0	502.2	481.9	456.3	464.0	481.5	460.9	443.6	474.4	464.8	-0.6 (-0.9; -0.2)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3.5. Lung Cancer Incidence Trends: Females, by age group, the number of new diagnoses, crude and age-standardised incidence rates, over the 2004-2022 period, including average annual percentage change

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
15-59																						
N	540	547	600	622	588	709	734	690	727	720	694	681	705	684	644	721	640	646	685			
CR	17.2	17.4	18.9	19.5	18.4	22.0	22.7	21.2	22.2	22.0	21.1	20.7	21.4	20.8	19.6	21.9	19.5	19.6	20.8			
ESR2013	18.1	18.1	19.5	20.0	18.8	22.5	23.0	21.3	22.2	21.8	20.9	20.2	20.9	20.2	19.0	21.2	18.8	19.0	20.3	0.4 (0.0; 0.8)	2004-2022	
																				3.8 (2.4; 5.2)	2004-2010	
																				-1.2 (-1.8; -0.6)	2011-2022	
60-74																						
N	627	641	688	784	796	875	955	1,074	1,058	1,190	1,282	1,289	1,363	1,495	1,669	1,696	1,846	1,924	2,035			
CR	80.9	82.7	89.1	100.5	101.0	109.4	117.9	130.5	126.8	140.5	149.4	147.8	152.8	162.9	177.5	176.9	188.9	193.5	202.6			
ESR2013	80.9	83.0	88.7	100.4	101.3	110.4	118.3	131.7	127.5	141.4	149.8	148.1	154.2	163.8	178.3	177.6	189.5	194.3	203.6	5.4 (5.1; 5.6)	2004-2022	
																				6.7 (6.1; 7.4)	2004-2012	
																				4.3 (3.8; 4.8)	2013-2022	
75+																						
N	387	404	415	473	430	496	559	583	583	592	697	703	686	704	807	850	840	956	1,013			
CR	74.4	76.1	76.2	84.9	75.5	85.8	95.3	98.3	97.2	98.0	114.2	113.9	111.3	114.9	132.0	138.4	135.4	154.5	159.8			
ESR2013	73.2	74.8	75.5	84.1	73.9	84.9	95.3	99.3	98.5	100.1	115.7	116.4	115.6	120.7	140.0	147.9	145.6	167.7	171.0	5.0 (4.5; 5.5)	2004-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.



3.1. Lung Cancer Prevalence: By region

3.1.1. Lung Cancer Prevalence: Region, by sex, the number of prevalent cases, crude and age-standardised prevalence rates

Region		Males				Females			
		1-year	5-year	10-year	15-year	1-year	5-year	10-year	15-year
Belgium	N	3,879	10,947	14,281	15,774	2,798	8,161	10,839	11,978
	CR	67.3	190.0	247.9	274	47.1	137.5	182.6	202
	ESR2013	70.8	200.2	261.9	289.8	45.2	131.4	174.1	192.0
Brussels	N	266	741	943	1,009	190	576	768	857
	CR	43.7	121.8	155.0	165.9	30.0	91.0	121.3	135.4
	ESR2013	67.3	187.1	239.6	256.9	38.9	118.4	158.1	176.3
Flanders	N	2,255	6,440	8,452	9,344	1,549	4,518	5,994	6,599
	CR	67.3	192.1	252.1	278.7	45.3	132.0	175.1	192.8
	ESR2013	66.3	189.3	248.8	275.3	41.6	121.0	160.0	175.8
Wallonia	N	1,357	3,756	4,872	5,402	1,058	3,066	4,071	4,513
	CR	75.4	208.6	270.5	300.0	56.3	163.0	216.5	240.0
	ESR2013	79.9	222.1	289.3	322.0	53.3	154.1	204.1	225.8



4.1. Lung Cancer Survival: By region

4.1.1. Lung Cancer Survival: Region, by sex and age group, the number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
		85,705	53.9% (53.6%; 54.2%)	32.7% (32.3%; 33.0%)	25.6% (25.3%; 26.0%)	16.9% (16.1%; 17.6%)
Males						
Belgium	15-59	8,630	58.2% (57.2%; 59.3%)	35.1% (34.1%; 36.2%)	28.3% (27.3%; 29.4%)	20.2% (18.9%; 21.6%)
	60-74	28,182	54.8% (54.2%; 55.4%)	32.7% (32.2%; 33.3%)	25.3% (24.7%; 25.9%)	15.9% (15.1%; 16.8%)
	75+	19,112	42.4% (41.6%; 43.1%)	22.1% (21.4%; 22.9%)	15.7% (14.9%; 16.5%)	8.8% (7.2%; 10.7%)
Brussels	15-59	887	59.8% (56.6%; 63.1%)	38.5% (35.3%; 42.0%)	31.7% (28.5%; 35.3%)	23.9% (19.7%; 29.0%)
	60-74	1,833	54.4% (52.1%; 56.7%)	30.2% (28.0%; 32.6%)	23.5% (21.2%; 25.9%)	14.5% (11.4%; 18.6%)
	75+	1,126	43.3% (40.3%; 46.5%)	22.0% (19.2%; 25.3%)	16.3% (13.3%; 20.1%)	7.7% (3.4%; 17.6%)
Flanders	15-59	4,186	59.6% (58.2%; 61.2%)	36.6% (35.1%; 38.1%)	29.7% (28.2%; 31.2%)	21.4% (19.4%; 23.5%)
	60-74	16,194	55.0% (54.2%; 55.8%)	32.7% (32.0%; 33.5%)	25.3% (24.6%; 26.1%)	16.2% (15.1%; 17.4%)
	75+	12,568	42.3% (41.4%; 43.2%)	21.9% (21.0%; 22.8%)	15.9% (14.9%; 16.8%)	10.1% (8.0%; 12.8%)
Wallonia	15-59	3,557	56.1% (54.5%; 57.8%)	32.6% (31.0%; 34.2%)	25.9% (24.4%; 27.5%)	17.7% (15.9%; 19.7%)
	60-74	10,158	54.7% (53.7%; 55.7%)	33.2% (32.2%; 34.2%)	25.5% (24.5%; 26.6%)	15.6% (14.2%; 17.2%)
	75+	5,418	42.4% (41.0%; 43.8%)	22.7% (21.4%; 24.1%)	15.1% (13.7%; 16.7%)	6.2% (4.2%; 9.0%)
Females						

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Belgium	15-59	6,716	67.2% (66.1%; 68.3%)	45.5% (44.3%; 46.8%)	38.3% (37.1%; 39.6%)	30.2% (28.6%; 31.8%)
	60-74	15,477	61.4% (60.6%; 62.2%)	40.4% (39.6%; 41.2%)	32.9% (32.0%; 33.8%)	22.2% (21.0%; 23.6%)
	75+	7,775	48.1% (47.0%; 49.3%)	29.5% (28.4%; 30.8%)	23.3% (22.0%; 24.7%)	14.2% (10.3%; 19.6%)
Brussels	15-59	530	64.9% (60.9%; 69.1%)	41.4% (37.2%; 46.0%)	35.1% (31.0%; 39.8%)	26.5% (21.3%; 32.8%)
	60-74	1,124	59.4% (56.6%; 62.4%)	39.4% (36.5%; 42.6%)	33.2% (30.2%; 36.5%)	22.5% (18.0%; 28.2%)
	75+	699	53.1% (49.3%; 57.2%)	32.8% (28.9%; 37.3%)	26.0% (21.7%; 31.1%)	25.8% (17.6%; 37.8%)
Flanders	15-59	3,412	66.7% (65.1%; 68.3%)	45.0% (43.3%; 46.8%)	37.5% (35.8%; 39.4%)	30.3% (28.1%; 32.6%)
	60-74	8,519	62.7% (61.7%; 63.7%)	41.0% (40.0%; 42.2%)	33.5% (32.3%; 34.6%)	23.3% (21.6%; 25.1%)
	75+	4,567	47.7% (46.2%; 49.3%)	29.0% (27.5%; 30.5%)	23.0% (21.3%; 24.8%)	12.9% (8.1%; 20.7%)
Wallonia	15-59	2,774	68.3% (66.6%; 70.0%)	46.9% (45.0%; 48.9%)	39.9% (37.9%; 41.9%)	30.7% (28.3%; 33.3%)
	60-74	5,837	59.8% (58.6%; 61.1%)	39.7% (38.3%; 41.0%)	32.0% (30.6%; 33.4%)	20.6% (18.7%; 22.8%)
	75+	2,509	47.5% (45.5%; 49.6%)	29.7% (27.6%; 31.9%)	23.1% (20.9%; 25.6%)	12.0% (7.3%; 19.9%)

4.2. Lung Cancer Survival: By stage for the histological types of lung cancer

4.2.2. Lung Cancer Survival: Clinical stage for the histological types of lung cancer, by sex, the number at risk and net survival probabilities, 2013-2022

Type	stage	Net Survival Probability, 2013-2022							
		N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
Total		85,705	53.9% (53.6%; 54.2%)	39.6% (39.2%; 39.9%)	32.7% (32.3%; 33.0%)	28.4% (28.1%; 28.8%)	25.6% (25.3%; 26.0%)	16.9% (16.1%; 17.6%)	
Males									
SCLC	I	238	77.6% (72.1%; 83.5%)	49.2% (42.8%; 56.6%)	37.8% (31.5%; 45.3%)	30.6% (24.5%; 38.3%)	29.9% (23.5%; 38.0%)	17.4% (10.3%; 29.4%)	
	II	207	70.9% (64.7%; 77.7%)	44.1% (37.5%; 51.9%)	36.2% (29.7%; 44.0%)	30.1% (23.8%; 38.0%)	28.2% (21.9%; 36.3%)	11.2% (4.6%; 27.3%)	
	III	1,574	55.9% (53.4%; 58.5%)	29.4% (27.2%; 31.9%)	22.0% (19.9%; 24.3%)	17.3% (15.4%; 19.6%)	15.0% (13.1%; 17.2%)	8.1% (5.8%; 11.4%)	
	IV	4,843	23.0% (21.8%; 24.2%)	6.6% (5.9%; 7.4%)	3.5% (3.0%; 4.2%)	2.5% (2.0%; 3.1%)	2.1% (1.6%; 2.7%)	1.3% (0.8%; 2.1%)	
	X/NA	755	23.0% (20.2%; 26.3%)	9.4% (7.4%; 11.8%)	7.3% (5.6%; 9.6%)	5.7% (4.2%; 7.8%)	4.8% (3.4%; 6.9%)	1.3% (0.5%; 3.6%)	
NSCLC	I	7,674	90.5% (89.8%; 91.3%)	81.2% (80.2%; 82.3%)	73.2% (72.0%; 74.5%)	66.5% (65.1%; 67.9%)	61.8% (60.2%; 63.3%)	42.4% (39.1%; 46.1%)	
	II	3,338	77.4% (75.9%; 79.0%)	62.7% (60.9%; 64.6%)	53.2% (51.2%; 55.2%)	46.6% (44.6%; 48.8%)	41.5% (39.3%; 43.7%)	25.7% (22.1%; 29.9%)	
	III	8,953	63.0% (61.9%; 64.0%)	43.4% (42.4%; 44.6%)	33.3% (32.2%; 34.4%)	27.5% (26.5%; 28.6%)	24.4% (23.3%; 25.5%)	15.6% (14.2%; 17.3%)	
	IV	19,123	33.0% (32.3%; 33.7%)	18.5% (18.0%; 19.1%)	12.8% (12.3%; 13.4%)	9.8% (9.3%; 10.3%)	8.0% (7.6%; 8.5%)	3.8% (3.0%; 4.7%)	
	X/NA	4,108	51.5% (50.0%; 53.1%)	40.7% (39.1%; 42.3%)	35.1% (33.6%; 36.8%)	30.9% (29.3%; 32.5%)	28.3% (26.7%; 29.9%)	18.8% (16.8%; 21.0%)	
SCC	I	2,950	87.4% (86.1%; 88.8%)	75.8% (74.0%; 77.6%)	66.9% (64.9%; 69.0%)	58.1% (55.9%; 60.5%)	51.8% (49.4%; 54.4%)	34.8% (30.3%; 39.9%)	
	II	1,674	76.2% (74.0%; 78.4%)	60.5% (58.0%; 63.2%)	49.1% (46.4%; 52.0%)	43.0% (40.1%; 46.0%)	37.3% (34.4%; 40.5%)	26.1% (21.9%; 31.2%)	
	III	4,656	61.1% (59.7%; 62.6%)	40.7% (39.2%; 42.3%)	30.1% (28.7%; 31.6%)	24.3% (22.9%; 25.8%)	21.4% (20.0%; 22.9%)	13.1% (11.2%; 15.2%)	
	IV	4,824	32.3% (30.9%; 33.7%)	15.7% (14.7%; 16.8%)	10.3% (9.4%; 11.3%)	7.6% (6.8%; 8.6%)	5.9% (5.1%; 6.9%)	3.2% (2.2%; 4.8%)	
	X/NA	1,489	48.9% (46.3%; 51.6%)	36.3% (33.7%; 39.0%)	30.8% (28.3%; 33.4%)	26.5% (24.1%; 29.2%)	24.0% (21.5%; 26.6%)	12.5% (9.9%; 15.7%)	
ADC	I	4,127	93.1% (92.2%; 94.0%)	85.6% (84.3%; 86.9%)	77.9% (76.3%; 79.5%)	72.3% (70.5%; 74.2%)	68.2% (66.1%; 70.3%)	46.4% (41.3%; 52.1%)	
	II	1,409	80.5% (78.3%; 82.8%)	66.6% (64.0%; 69.4%)	59.6% (56.7%; 62.6%)	52.2% (49.1%; 55.6%)	47.4% (44.1%; 50.9%)	21.7% (15.5%; 30.4%)	
	III	3,545	67.1% (65.5%; 68.7%)	48.3% (46.6%; 50.1%)	38.1% (36.3%; 39.9%)	31.8% (30.1%; 33.6%)	28.1% (26.3%; 30.0%)	17.2% (14.7%; 20.2%)	

Net Survival Probability, 2013-2022									
Type	stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
LCC	IV	12,299	34.9% (34.0%; 35.7%)	20.6% (19.9%; 21.4%)	14.4% (13.7%; 15.1%)	11.1% (10.5%; 11.8%)	9.2% (8.5%; 9.8%)	4.1% (3.1%; 5.3%)	
	X/NA	2,118	56.5% (54.4%; 58.8%)	46.3% (44.1%; 48.6%)	40.5% (38.3%; 42.9%)	35.7% (33.4%; 38.1%)	32.7% (30.4%; 35.1%)	23.1% (20.1%; 26.5%)	
	I	86	81.4% (72.7%; 91.2%)	63.8% (53.2%; 76.4%)	53.4% (42.4%; 67.2%)	48.6% (36.7%; 64.4%)	41.4% (29.5%; 58.1%)	23.1% (11.2%; 48.0%)	
	II	60	69.3% (58.1%; 82.7%)	62.2% (50.1%; 77.1%)	48.7% (35.7%; 66.4%)	45.0% (31.3%; 64.7%)	34.6% (19.9%; 60.1%)	20.1% (6.3%; 64.8%)	
	III	204	51.9% (45.3%; 59.5%)	36.8% (30.5%; 44.5%)	30.6% (24.4%; 38.4%)	24.8% (18.7%; 32.8%)	24.2% (18.1%; 32.5%)	17.4% (10.4%; 29.3%)	
	IV	635	21.0% (18.0%; 24.5%)	10.1% (7.9%; 13.0%)	7.4% (5.4%; 10.1%)	4.0% (2.4%; 6.7%)	3.7% (2.1%; 6.3%)	-	
	X/NA	144	21.3% (15.5%; 29.4%)	14.3% (9.4%; 21.8%)	10.8% (6.5%; 17.8%)	10.1% (5.9%; 17.3%)	9.7% (5.5%; 17.0%)	-	
	I	567	89.7% (86.9%; 92.6%)	81.2% (77.5%; 85.0%)	75.1% (70.7%; 79.6%)	71.0% (66.2%; 76.2%)	70.5% (65.4%; 76.0%)	59.0% (49.4%; 70.3%)	
	II	209	70.0% (63.7%; 76.9%)	55.9% (49.0%; 63.8%)	46.6% (39.2%; 55.3%)	40.6% (33.2%; 49.7%)	40.4% (32.4%; 50.5%)	29.1% (17.5%; 48.3%)	
	III	564	56.1% (52.0%; 60.6%)	37.9% (33.9%; 42.4%)	31.5% (27.5%; 36.0%)	29.0% (25.0%; 33.7%)	25.1% (20.9%; 30.2%)	23.5% (18.1%; 30.5%)	
Other	IV	1,374	24.6% (22.3%; 27.0%)	13.9% (12.2%; 16.0%)	10.6% (9.0%; 12.5%)	8.2% (6.7%; 10.1%)	7.2% (5.7%; 9.1%)	4.1% (2.4%; 6.8%)	
	X/NA	378	48.1% (43.1%; 53.6%)	38.7% (33.9%; 44.3%)	34.2% (29.4%; 39.8%)	31.9% (27.0%; 37.6%)	29.4% (24.5%; 35.2%)	26.2% (20.1%; 34.0%)	
	I	2,139	82.6% (80.7%; 84.5%)	66.6% (64.2%; 69.0%)	55.0% (52.4%; 57.8%)	45.9% (42.9%; 49.1%)	39.3% (36.1%; 42.9%)	18.2% (11.2%; 29.3%)	
	II	442	60.6% (55.8%; 65.9%)	41.7% (36.7%; 47.4%)	29.5% (24.6%; 35.5%)	24.0% (19.1%; 30.2%)	22.8% (17.5%; 29.6%)	13.9% (7.1%; 27.2%)	
	III	795	34.6% (31.3%; 38.3%)	19.7% (16.8%; 23.1%)	13.3% (10.7%; 16.5%)	10.5% (8.0%; 13.9%)	8.0% (5.6%; 11.3%)	6.2% (2.7%; 14.5%)	
	IV	1,711	10.9% (9.4%; 12.5%)	5.2% (4.1%; 6.5%)	2.7% (1.9%; 3.9%)	2.4% (1.6%; 3.6%)	1.6% (0.9%; 2.8%)	0.8% (0.3%; 2.6%)	
X/NA	508	52.9% (48.4%; 57.7%)	39.7% (35.3%; 44.8%)	36.1% (31.4%; 41.5%)	31.0% (26.1%; 36.7%)	25.7% (20.8%; 31.7%)	10.0% (3.2%; 30.6%)		
Females									
SCLC	I	171	84.4% (78.9%; 90.3%)	61.9% (54.6%; 70.0%)	49.8% (42.3%; 58.7%)	40.2% (32.6%; 49.6%)	37.5% (29.8%; 47.3%)	30.7% (21.4%; 44.0%)	
	II	137	74.8% (67.7%; 82.7%)	54.1% (46.0%; 63.5%)	46.4% (38.2%; 56.4%)	38.3% (29.8%; 49.3%)	33.2% (24.7%; 44.7%)	13.0% (4.8%; 35.4%)	
	III	1,078	63.5% (60.6%; 66.5%)	38.4% (35.5%; 41.5%)	28.2% (25.4%; 31.2%)	22.4% (19.8%; 25.3%)	20.4% (17.8%; 23.4%)	11.8% (8.8%; 15.9%)	
	IV	2,721	30.0% (28.4%; 31.8%)	11.7% (10.5%; 13.0%)	6.8% (5.8%; 7.9%)	4.9% (4.1%; 5.9%)	3.9% (3.1%; 4.9%)	2.7% (1.9%; 3.8%)	
	X/NA	404	35.3% (30.9%; 40.3%)	19.7% (16.1%; 24.0%)	14.0% (10.9%; 18.0%)	12.5% (9.5%; 16.4%)	10.6% (7.8%; 14.4%)	5.0% (2.7%; 9.5%)	
NSCLC	I	5,022	94.9% (94.2%; 95.6%)	89.0% (88.0%; 90.0%)	83.7% (82.5%; 85.0%)	79.9% (78.4%; 81.3%)	75.4% (73.7%; 77.1%)	56.4% (52.5%; 60.6%)	

Type	stage	N at risk	Net Survival Probability, 2013-2022						
			1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
SCC	II	1,449	83.6% (81.6%; 85.6%)	71.2% (68.8%; 73.8%)	64.1% (61.4%; 66.9%)	57.9% (54.9%; 61.0%)	52.3% (49.1%; 55.7%)	31.3% (22.4%; 43.6%)	
	III	3,841	68.2% (66.7%; 69.7%)	50.8% (49.2%; 52.5%)	42.0% (40.3%; 43.7%)	36.8% (35.1%; 38.5%)	32.9% (31.2%; 34.7%)	21.7% (19.3%; 24.4%)	
	IV	10,430	43.0% (42.0%; 43.9%)	27.6% (26.7%; 28.5%)	20.0% (19.2%; 20.9%)	16.0% (15.2%; 16.8%)	13.4% (12.6%; 14.2%)	7.0% (6.0%; 8.2%)	
	X/NA	2,133	62.9% (60.9%; 65.1%)	54.9% (52.8%; 57.2%)	49.7% (47.5%; 52.1%)	46.9% (44.6%; 49.3%)	44.1% (41.8%; 46.6%)	37.7% (34.5%; 41.2%)	
	I	909	90.9% (88.9%; 93.0%)	80.0% (77.1%; 82.9%)	71.4% (68.1%; 74.9%)	65.9% (62.2%; 69.7%)	58.1% (54.0%; 62.4%)	33.3% (26.6%; 41.7%)	
	II	412	76.7% (72.5%; 81.0%)	60.7% (55.9%; 65.9%)	51.4% (46.3%; 57.1%)	44.6% (39.3%; 50.6%)	39.2% (33.7%; 45.6%)	26.1% (17.9%; 38.1%)	
	III	1,190	59.0% (56.2%; 62.0%)	39.0% (36.2%; 42.0%)	30.2% (27.6%; 33.2%)	27.2% (24.6%; 30.2%)	23.9% (21.2%; 26.9%)	15.0% (11.7%; 19.2%)	
ADC	IV	1,320	34.9% (32.4%; 37.6%)	19.1% (17.1%; 21.4%)	12.9% (11.1%; 15.0%)	10.2% (8.5%; 12.2%)	8.9% (7.2%; 11.0%)	5.1% (3.1%; 8.5%)	
	X/NA	393	61.1% (56.4%; 66.3%)	51.3% (46.4%; 56.7%)	44.3% (39.3%; 49.9%)	40.8% (35.8%; 46.5%)	38.0% (33.0%; 43.7%)	25.7% (19.7%; 33.6%)	
	I	3,428	95.7% (94.9%; 96.5%)	90.5% (89.3%; 91.6%)	85.3% (83.8%; 86.8%)	81.4% (79.7%; 83.2%)	77.0% (75.0%; 79.1%)	57.4% (52.6%; 62.7%)	
	II	877	86.3% (83.9%; 88.7%)	75.3% (72.3%; 78.5%)	68.7% (65.3%; 72.2%)	62.3% (58.6%; 66.3%)	55.5% (51.4%; 60.0%)	31.3% (20.0%; 49.0%)	
	III	2,295	73.8% (72.0%; 75.7%)	58.0% (55.9%; 60.1%)	48.7% (46.6%; 51.0%)	41.9% (39.7%; 44.2%)	37.4% (35.1%; 39.8%)	25.9% (22.5%; 29.7%)	
	IV	8,160	45.7% (44.7%; 46.9%)	30.0% (29.0%; 31.1%)	21.8% (20.9%; 22.8%)	17.3% (16.3%; 18.2%)	14.3% (13.4%; 15.2%)	7.3% (6.1%; 8.7%)	
	X/NA	1,439	63.7% (61.2%; 66.3%)	55.0% (52.4%; 57.8%)	50.0% (47.3%; 52.9%)	47.3% (44.6%; 50.2%)	44.2% (41.3%; 47.2%)	36.6% (32.6%; 41.1%)	
LCC	I	48	N<50	N<50	N<50	N<50	N<50	N<50	
	II	29	N<50	N<50	N<50	N<50	N<50	N<50	
	III	85	59.9% (50.2%; 71.6%)	40.8% (31.2%; 53.5%)	34.1% (24.9%; 46.8%)	32.1% (22.8%; 45.2%)	32.4% (23.0%; 45.7%)	-	
	IV	274	22.3% (17.8%; 27.8%)	12.1% (8.7%; 16.7%)	8.6% (5.7%; 13.1%)	8.7% (5.8%; 13.2%)	8.8% (5.8%; 13.3%)	-	
	X/NA	52	29.2% (19.2%; 44.4%)	27.7% (17.9%; 42.9%)	21.9% (13.0%; 36.7%)	22.1% (13.2%; 37.2%)	20.1% (11.5%; 35.1%)	16.8% (8.8%; 31.9%)	
Other NSCLC	I	682	97.2% (95.7%; 98.8%)	94.5% (92.4%; 96.7%)	93.0% (90.4%; 95.7%)	91.3% (88.2%; 94.5%)	90.4% (86.8%; 94.2%)	81.2% (70.4%; 93.7%)	
	II	141	87.9% (82.4%; 93.8%)	76.6% (69.3%; 84.5%)	72.8% (64.9%; 81.6%)	70.4% (61.9%; 80.2%)	71.8% (62.8%; 82.1%)	61.5% (46.6%; 81.3%)	
	III	273	63.0% (57.4%; 69.1%)	45.9% (40.1%; 52.5%)	38.9% (33.1%; 45.7%)	37.1% (31.2%; 44.3%)	35.9% (29.6%; 43.4%)	18.4% (11.1%; 30.6%)	
	IV	681	33.6% (30.2%; 37.3%)	20.9% (18.0%; 24.3%)	17.1% (14.4%; 20.4%)	14.6% (11.9%; 17.8%)	13.1% (10.6%; 16.4%)	7.8% (4.8%; 12.6%)	
	X/NA	261	69.8% (64.3%; 75.8%)	66.2% (60.5%; 72.5%)	63.2% (57.2%; 69.8%)	59.3% (53.1%; 66.3%)	59.1% (52.7%; 66.3%)	64.3% (56.6%; 73.0%)	
Other	I	1,264	84.9% (82.7%; 87.1%)	73.0% (70.2%; 75.8%)	63.1% (59.9%; 66.5%)	54.9% (51.3%; 58.8%)	49.9% (46.0%; 54.1%)	29.0% (22.1%; 38.1%)	

Net Survival Probability, 2013-2022								
Type	stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	II	197	60.8% (53.9%; 68.5%)	45.5% (38.3%; 54.0%)	36.4% (29.0%; 45.6%)	29.1% (21.4%; 39.6%)	30.1% (21.7%; 41.7%)	25.5% (12.9%; 50.6%)
	III	330	36.9% (31.8%; 42.8%)	22.3% (17.9%; 27.9%)	15.4% (11.5%; 20.7%)	14.3% (10.3%; 19.8%)	9.6% (6.2%; 14.8%)	6.0% (2.3%; 15.3%)
	IV	748	15.5% (13.0%; 18.4%)	10.2% (8.1%; 12.9%)	9.0% (6.8%; 11.8%)	9.0% (6.7%; 12.1%)	10.0% (7.3%; 13.5%)	1.5% (0.2%; 9.9%)
	X/NA	303	62.0% (56.5%; 68.0%)	52.4% (46.6%; 59.0%)	49.0% (42.9%; 56.0%)	44.8% (38.2%; 52.6%)	42.1% (35.1%; 50.6%)	17.6% (7.1%; 43.4%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

4.2.3. Lung Cancer Survival: Pathological stage for the histological types of lung cancer, by sex, the number at risk and net survival probabilities, 2013-2022

Type	Net Survival Probability, 2013-2022								
	stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
Total		85,705	53.9% (53.6%; 54.2%)	39.6% (39.2%; 39.9%)	32.7% (32.3%; 33.0%)	28.4% (28.1%; 28.8%)	25.6% (25.3%; 26.0%)	16.9% (16.1%; 17.6%)	
Males									
SCLC	I	97	85.4% (78.2%; 93.4%)	59.5% (49.8%; 71.0%)	51.7% (41.7%; 64.1%)	42.3% (32.2%; 55.6%)	42.0% (31.6%; 55.7%)	22.4% (10.7%; 46.7%)	
	II	67	74.8% (64.7%; 86.5%)	51.5% (40.5%; 65.6%)	46.4% (35.4%; 61.0%)	42.9% (31.8%; 57.8%)	42.3% (31.0%; 57.7%)	19.7% (9.0%; 42.7%)	
	III	102	39.2% (30.7%; 50.0%)	21.3% (14.5%; 31.2%)	14.2% (8.7%; 23.2%)	11.0% (6.1%; 19.6%)	8.9% (4.6%; 17.1%)	-	
	IV	609	19.5% (16.6%; 23.0%)	6.1% (4.4%; 8.3%)	2.9% (1.8%; 4.7%)	2.2% (1.2%; 4.0%)	1.6% (0.8%; 3.4%)	0.7% (0.2%; 2.5%)	
	X/NA	6,742	32.7% (31.6%; 33.9%)	13.6% (12.7%; 14.4%)	9.3% (8.6%; 10.1%)	7.2% (6.5%; 7.9%)	6.2% (5.6%; 6.9%)	3.4% (2.6%; 4.4%)	
NSCLC	I	5,807	95.1% (94.4%; 95.8%)	90.2% (89.2%; 91.1%)	85.4% (84.3%; 86.6%)	81.1% (79.8%; 82.5%)	77.5% (75.9%; 79.1%)	58.2% (54.8%; 61.8%)	
	II	2,504	89.0% (87.6%; 90.4%)	77.9% (76.1%; 79.8%)	71.1% (69.0%; 73.2%)	63.8% (61.6%; 66.2%)	58.9% (56.5%; 61.5%)	45.0% (40.6%; 49.8%)	
	III	1,706	76.3% (74.2%; 78.5%)	58.9% (56.4%; 61.4%)	48.8% (46.2%; 51.5%)	42.4% (39.8%; 45.2%)	37.9% (35.1%; 40.8%)	25.6% (20.8%; 31.5%)	
	IV	2,983	32.4% (30.8%; 34.2%)	20.1% (18.7%; 21.7%)	15.4% (14.0%; 16.8%)	12.2% (10.9%; 13.6%)	10.3% (9.1%; 11.7%)	6.2% (4.6%; 8.4%)	
	X/NA	30,147	45.0% (44.4%; 45.6%)	28.6% (28.1%; 29.2%)	20.7% (20.2%; 21.2%)	16.1% (15.6%; 16.6%)	13.4% (12.9%; 13.9%)	6.0% (5.3%; 6.9%)	
SCC	I	1,935	93.2% (91.8%; 94.5%)	86.6% (84.8%; 88.5%)	81.1% (78.9%; 83.3%)	75.5% (73.0%; 78.1%)	69.9% (67.1%; 72.8%)	48.5% (43.1%; 54.5%)	
	II	1,086	89.5% (87.4%; 91.6%)	78.4% (75.6%; 81.2%)	72.3% (69.2%; 75.5%)	65.8% (62.4%; 69.4%)	59.6% (55.8%; 63.6%)	49.7% (43.3%; 57.1%)	
	III	639	77.1% (73.7%; 80.6%)	58.2% (54.3%; 62.5%)	47.7% (43.6%; 52.2%)	40.4% (36.2%; 45.1%)	36.8% (32.4%; 41.7%)	25.3% (19.7%; 32.3%)	
	IV	484	30.6% (26.7%; 35.1%)	16.3% (13.2%; 20.1%)	12.2% (9.5%; 15.8%)	10.4% (7.8%; 13.9%)	7.6% (5.3%; 11.0%)	-	
	X/NA	11,449	48.7% (47.7%; 49.6%)	30.2% (29.4%; 31.2%)	21.2% (20.4%; 22.1%)	16.0% (15.2%; 16.8%)	13.2% (12.4%; 14.0%)	5.9% (4.9%; 7.1%)	
ADC	I	3,424	96.3% (95.5%; 97.1%)	92.5% (91.3%; 93.7%)	87.9% (86.5%; 89.4%)	84.1% (82.3%; 85.8%)	81.0% (79.1%; 83.1%)	61.3% (56.7%; 66.3%)	
	II	1,245	89.5% (87.7%; 91.4%)	78.0% (75.5%; 80.7%)	70.4% (67.5%; 73.5%)	62.5% (59.3%; 65.9%)	57.9% (54.5%; 61.5%)	37.3% (31.2%; 44.6%)	
	III	917	76.9% (74.1%; 79.8%)	59.7% (56.4%; 63.2%)	49.1% (45.7%; 52.8%)	43.2% (39.6%; 47.0%)	38.1% (34.5%; 42.1%)	24.6% (17.8%; 34.0%)	
	IV	2,117	33.9% (31.9%; 36.0%)	21.5% (19.7%; 23.4%)	16.4% (14.8%; 18.2%)	13.0% (11.5%; 14.7%)	11.2% (9.7%; 13.0%)	7.1% (5.2%; 9.7%)	
	X/NA	15,805	44.4% (43.6%; 45.2%)	28.9% (28.2%; 29.7%)	21.2% (20.5%; 21.9%)	16.7% (16.0%; 17.4%)	13.9% (13.2%; 14.6%)	5.9% (4.7%; 7.3%)	

		Net Survival Probability, 2013-2022							
Type	stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
LCC	I	46	N<50	N<50	N<50	N<50	N<50	N<50	
	II	39	N<50	N<50	N<50	N<50	N<50	N<50	
	III	37	N<50	N<50	N<50	N<50	N<50	N<50	
	IV	112	24.9% (18.0%; 34.5%)	14.0% (8.6%; 22.9%)	10.6% (5.9%; 19.2%)	7.3% (3.3%; 15.9%)	7.3% (3.3%; 16.0%)	-	
	X/NA	895	28.9% (26.0%; 32.1%)	17.7% (15.2%; 20.6%)	13.3% (11.0%; 16.0%)	10.1% (7.9%; 12.9%)	8.1% (5.9%; 11.1%)	2.3% (0.9%; 6.3%)	
Other NSCLC	I	463	95.0% (92.6%; 97.4%)	89.6% (86.3%; 93.0%)	87.2% (83.3%; 91.2%)	85.0% (80.6%; 89.6%)	84.4% (79.6%; 89.5%)	77.5% (68.2%; 88.1%)	
	II	139	81.1% (74.5%; 88.3%)	73.5% (65.9%; 82.1%)	67.1% (58.7%; 76.7%)	59.9% (50.7%; 70.7%)	61.6% (52.2%; 72.8%)	54.1% (38.9%; 75.2%)	
	III	113	74.9% (66.9%; 83.7%)	63.4% (54.5%; 73.8%)	58.1% (48.7%; 69.3%)	52.9% (43.1%; 64.9%)	46.3% (36.2%; 59.3%)	42.8% (30.9%; 59.3%)	
	IV	270	27.4% (22.5%; 33.3%)	18.8% (14.6%; 24.4%)	14.8% (10.9%; 20.2%)	10.5% (7.0%; 15.7%)	9.5% (6.1%; 14.8%)	6.3% (3.1%; 12.6%)	
	X/NA	2,108	37.1% (35.0%; 39.3%)	23.3% (21.5%; 25.3%)	17.8% (16.0%; 19.7%)	15.3% (13.6%; 17.2%)	13.3% (11.6%; 15.4%)	8.2% (5.7%; 11.8%)	
Other	I	0	N<50	N<50	N<50	N<50	N<50	N<50	
	II	1	N<50	N<50	N<50	N<50	N<50	N<50	
	III	1	N<50	N<50	N<50	N<50	N<50	N<50	
	IV	7	N<50	N<50	N<50	N<50	N<50	N<50	
	X/NA	5,582	49.4% (48.0%; 50.8%)	36.8% (35.4%; 38.2%)	29.3% (27.9%; 30.8%)	24.5% (23.0%; 26.0%)	20.7% (19.2%; 22.4%)	9.8% (6.5%; 14.9%)	
Females									
SCLC	I	75	94.1% (88.6%; 99.9%)	79.9% (70.9%; 90.0%)	68.8% (58.4%; 81.0%)	60.3% (49.1%; 74.0%)	56.5% (44.9%; 71.0%)	48.1% (33.7%; 68.6%)	
	II	33	N<50	N<50	N<50	N<50	N<50	N<50	
	III	35	N<50	N<50	N<50	N<50	N<50	N<50	
	IV	329	30.0% (25.4%; 35.4%)	11.8% (8.7%; 16.0%)	7.0% (4.6%; 10.6%)	5.1% (3.1%; 8.4%)	4.0% (2.2%; 7.3%)	-	
	X/NA	4,039	41.3% (39.8%; 42.9%)	21.1% (19.8%; 22.4%)	14.6% (13.4%; 15.8%)	11.5% (10.5%; 12.7%)	10.0% (9.0%; 11.2%)	5.5% (4.4%; 7.0%)	
NSCLC	I	4,107	98.4% (97.9%; 98.9%)	96.0% (95.3%; 96.8%)	92.8% (91.7%; 93.8%)	90.1% (88.8%; 91.4%)	86.9% (85.4%; 88.4%)	74.6% (71.0%; 78.4%)	
	II	1,236	91.2% (89.6%; 92.9%)	84.2% (82.0%; 86.4%)	80.1% (77.6%; 82.6%)	74.3% (71.4%; 77.2%)	69.2% (65.9%; 72.5%)	50.0% (43.8%; 57.0%)	
	III	923	84.7% (82.3%; 87.1%)	72.3% (69.4%; 75.4%)	63.4% (60.1%; 66.8%)	57.0% (53.5%; 60.7%)	51.2% (47.4%; 55.2%)	38.2% (32.9%; 44.2%)	

Type	stage	N at risk	Net Survival Probability, 2013-2022						
			1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
SCC	IV	1,682	43.2% (40.9%; 45.7%)	29.7% (27.6%; 32.1%)	22.2% (20.2%; 24.4%)	18.4% (16.4%; 20.6%)	15.5% (13.6%; 17.6%)	8.9% (6.8%; 11.7%)	
	X/NA	14,901	51.9% (51.0%; 52.7%)	35.8% (35.0%; 36.6%)	27.6% (26.9%; 28.4%)	23.2% (22.4%; 24.0%)	20.0% (19.2%; 20.8%)	10.9% (9.6%; 12.5%)	
	I	618	96.7% (95.0%; 98.4%)	92.2% (89.7%; 94.8%)	86.8% (83.6%; 90.1%)	81.5% (77.7%; 85.5%)	75.9% (71.5%; 80.5%)	53.2% (45.2%; 62.6%)	
	II	260	88.1% (84.0%; 92.3%)	79.1% (74.0%; 84.6%)	75.5% (69.9%; 81.6%)	69.4% (63.2%; 76.3%)	61.7% (54.7%; 69.6%)	48.2% (35.9%; 64.6%)	
	III	155	78.5% (72.1%; 85.4%)	59.8% (52.3%; 68.5%)	48.9% (41.1%; 58.1%)	44.6% (36.8%; 54.2%)	43.7% (35.7%; 53.6%)	34.7% (24.2%; 49.8%)	
	IV	125	37.4% (29.7%; 46.9%)	18.1% (12.4%; 26.5%)	14.6% (9.4%; 22.6%)	13.8% (8.8%; 21.9%)	10.9% (6.2%; 19.3%)	-	
ADC	X/NA	3,066	50.6% (48.8%; 52.4%)	32.7% (31.0%; 34.5%)	24.0% (22.4%; 25.7%)	20.5% (19.0%; 22.2%)	17.2% (15.7%; 18.9%)	7.9% (6.0%; 10.4%)	
	I	2,895	98.5% (97.9%; 99.1%)	96.2% (95.2%; 97.1%)	92.9% (91.6%; 94.1%)	90.5% (89.0%; 92.0%)	87.3% (85.5%; 89.1%)	74.6% (70.2%; 79.2%)	
	II	820	92.5% (90.5%; 94.4%)	85.5% (82.9%; 88.2%)	80.9% (77.9%; 84.0%)	74.7% (71.3%; 78.4%)	69.3% (65.4%; 73.5%)	48.0% (40.6%; 56.8%)	
	III	657	86.0% (83.3%; 88.8%)	75.1% (71.7%; 78.7%)	65.7% (61.9%; 69.8%)	58.4% (54.3%; 62.8%)	50.7% (46.3%; 55.6%)	35.7% (29.6%; 43.0%)	
	IV	1,355	45.2% (42.6%; 48.0%)	31.7% (29.3%; 34.4%)	23.4% (21.1%; 25.9%)	19.2% (16.9%; 21.7%)	16.0% (13.8%; 18.4%)	9.2% (7.0%; 12.2%)	
	X/NA	10,457	53.4% (52.4%; 54.3%)	37.4% (36.5%; 38.4%)	29.0% (28.0%; 29.9%)	23.9% (23.0%; 24.9%)	20.4% (19.5%; 21.4%)	10.7% (8.8%; 13.0%)	
LCC	I	24	N<50	N<50	N<50	N<50	N<50	N<50	
	II	20	N<50	N<50	N<50	N<50	N<50	N<50	
	III	23	N<50	N<50	N<50	N<50	N<50	N<50	
	IV	48	N<50	N<50	N<50	N<50	N<50	N<50	
	X/NA	373	33.7% (29.2%; 38.9%)	22.2% (18.2%; 27.0%)	18.1% (14.4%; 22.7%)	16.6% (12.9%; 21.2%)	16.6% (12.8%; 21.4%)	8.8% (4.2%; 18.3%)	
	I	612	99.5% (98.5%; 100.6%)	99.1% (97.7%; 100.6%)	97.9% (95.8%; 100.0%)	95.8% (93.1%; 98.7%)	95.6% (92.5%; 98.9%)	99.3% (92.3%; 106.9%)	
Other NSCLC	II	139	93.9% (89.6%; 98.3%)	89.9% (84.3%; 95.9%)	89.3% (83.3%; 95.8%)	87.1% (80.1%; 94.7%)	88.5% (81.4%; 96.3%)	68.1% (51.8%; 89.5%)	
	III	88	85.0% (77.7%; 93.1%)	74.2% (65.2%; 84.4%)	71.0% (61.5%; 82.0%)	68.2% (58.0%; 80.1%)	67.5% (57.0%; 79.9%)	60.1% (44.9%; 80.5%)	
	IV	154	37.5% (30.6%; 46.0%)	26.5% (20.3%; 34.6%)	21.7% (15.9%; 29.6%)	17.6% (12.2%; 25.4%)	16.1% (10.9%; 23.9%)	9.3% (4.0%; 21.7%)	
	X/NA	1,045	47.7% (44.7%; 50.8%)	34.0% (31.1%; 37.1%)	29.2% (26.4%; 32.3%)	26.9% (24.1%; 30.1%)	25.6% (22.6%; 28.9%)	18.5% (14.5%; 23.7%)	
	I	1	N<50	N<50	N<50	N<50	N<50	N<50	
	II	0	N<50	N<50	N<50	N<50	N<50	N<50	
Other	III	0	N<50	N<50	N<50	N<50	N<50	N<50	

Net Survival Probability, 2013-2022								
Type	stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	IV	6	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	2,833	57.1% (55.2%; 59.1%)	46.6% (44.6%; 48.6%)	40.0% (37.9%; 42.2%)	35.3% (33.1%; 37.6%)	32.4% (30.1%; 34.9%)	15.8% (8.6%; 29.0%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

4.2.4. Lung Cancer Survival: Stage for the histological types of lung cancer, by sex, the number at risk and net survival probabilities, 2013-2022

Type	Stage	Net Survival Probability, 2013-2022							
		N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
Total		85,705	53.9% (53.6%; 54.2%)	39.6% (39.2%; 39.9%)	32.7% (32.3%; 33.0%)	28.4% (28.1%; 28.8%)	25.6% (25.3%; 26.0%)	16.9% (16.1%; 17.6%)	
Males									
SCLC	I	237	79.2% (73.8%; 85.0%)	51.6% (45.1%; 59.0%)	40.6% (34.1%; 48.2%)	32.5% (26.2%; 40.3%)	31.0% (24.5%; 39.2%)	17.4% (9.9%; 30.6%)	
	II	232	72.5% (66.7%; 78.8%)	46.2% (39.9%; 53.5%)	39.0% (32.8%; 46.4%)	33.1% (27.0%; 40.6%)	31.8% (25.7%; 39.5%)	12.2% (5.8%; 25.7%)	
	III	1,573	55.7% (53.2%; 58.3%)	29.3% (27.0%; 31.7%)	21.8% (19.7%; 24.1%)	17.1% (15.2%; 19.3%)	14.8% (12.9%; 17.0%)	8.4% (6.1%; 11.7%)	
	IV	4,899	22.8% (21.7%; 24.1%)	6.6% (5.9%; 7.3%)	3.5% (3.0%; 4.1%)	2.5% (2.0%; 3.1%)	2.1% (1.6%; 2.6%)	1.3% (0.8%; 2.1%)	
	X/NA	676	21.5% (18.6%; 24.9%)	7.6% (5.8%; 10.0%)	5.5% (3.9%; 7.6%)	4.2% (2.8%; 6.1%)	3.2% (2.0%; 5.1%)	-	
NSCLC	I	8,146	91.2% (90.5%; 92.0%)	82.9% (81.9%; 83.9%)	75.4% (74.2%; 76.6%)	69.0% (67.7%; 70.4%)	64.5% (63.0%; 66.0%)	44.5% (41.5%; 47.7%)	
	II	3,866	79.9% (78.5%; 81.2%)	65.4% (63.7%; 67.1%)	56.3% (54.5%; 58.2%)	49.4% (47.5%; 51.4%)	44.5% (42.5%; 46.6%)	31.5% (28.3%; 35.1%)	
	III	9,203	63.2% (62.2%; 64.2%)	43.5% (42.4%; 44.6%)	33.1% (32.1%; 34.2%)	27.3% (26.3%; 28.4%)	24.0% (22.9%; 25.1%)	14.5% (12.9%; 16.3%)	
	IV	19,444	33.0% (32.3%; 33.6%)	18.5% (18.0%; 19.1%)	12.9% (12.4%; 13.4%)	9.8% (9.3%; 10.3%)	8.1% (7.6%; 8.6%)	3.9% (3.1%; 4.8%)	
	X/NA	2,524	33.6% (31.7%; 35.5%)	21.5% (19.8%; 23.2%)	15.6% (14.1%; 17.3%)	12.0% (10.6%; 13.5%)	9.5% (8.1%; 11.0%)	3.6% (2.4%; 5.5%)	
SCC	I	3,102	87.6% (86.3%; 89.0%)	76.7% (75.0%; 78.5%)	67.9% (65.9%; 69.9%)	59.4% (57.3%; 61.7%)	53.3% (51.0%; 55.8%)	33.7% (29.7%; 38.3%)	
	II	1,926	78.3% (76.3%; 80.3%)	63.2% (60.9%; 65.7%)	53.2% (50.7%; 55.9%)	46.7% (44.0%; 49.5%)	41.1% (38.3%; 44.1%)	31.6% (27.4%; 36.4%)	
	III	4,652	60.9% (59.5%; 62.4%)	40.1% (38.7%; 41.7%)	29.3% (27.9%; 30.8%)	23.4% (22.0%; 24.9%)	20.7% (19.3%; 22.2%)	11.8% (10.0%; 13.9%)	
	IV	4,892	32.3% (30.9%; 33.6%)	15.7% (14.6%; 16.8%)	10.3% (9.4%; 11.3%)	7.7% (6.9%; 8.7%)	6.0% (5.2%; 7.0%)	3.1% (2.1%; 4.7%)	
	X/NA	1,022	34.0% (31.2%; 37.2%)	20.7% (18.2%; 23.5%)	14.9% (12.7%; 17.5%)	11.4% (9.3%; 13.9%)	8.8% (6.9%; 11.3%)	2.5% (1.1%; 5.7%)	
ADC	I	4,435	94.0% (93.1%; 94.9%)	87.7% (86.5%; 88.9%)	80.8% (79.4%; 82.4%)	75.5% (73.8%; 77.3%)	71.6% (69.7%; 73.6%)	49.8% (45.3%; 54.7%)	
	II	1,642	83.0% (81.0%; 85.0%)	68.8% (66.4%; 71.3%)	61.0% (58.4%; 63.8%)	53.2% (50.3%; 56.2%)	48.6% (45.6%; 51.8%)	29.8% (24.8%; 35.7%)	
	III	3,768	67.7% (66.2%; 69.3%)	48.9% (47.2%; 50.6%)	38.4% (36.7%; 40.1%)	32.2% (30.5%; 34.0%)	28.1% (26.4%; 29.9%)	17.2% (14.4%; 20.4%)	
	IV	12,517	34.8% (33.9%; 35.6%)	20.6% (19.9%; 21.3%)	14.4% (13.8%; 15.1%)	11.1% (10.5%; 11.7%)	9.2% (8.6%; 9.8%)	4.2% (3.3%; 5.5%)	
	X/NA	1,135	35.6% (32.8%; 38.6%)	23.3% (20.8%; 26.0%)	16.8% (14.6%; 19.4%)	12.5% (10.4%; 14.9%)	9.4% (7.5%; 11.8%)	3.1% (1.7%; 5.8%)	
LCC	I	91	84.0% (75.8%; 93.1%)	67.7% (57.5%; 79.8%)	56.8% (45.9%; 70.3%)	50.9% (39.1%; 66.4%)	43.5% (31.7%; 59.7%)	20.7% (9.7%; 44.1%)	

Type	Stage	N at risk	Net Survival Probability, 2013-2022						
			1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
Other NSCLC	II	71	75.8% (65.9%; 87.1%)	68.4% (57.5%; 81.4%)	56.6% (44.6%; 71.9%)	56.0% (43.1%; 72.8%)	46.7% (31.8%; 68.6%)	34.4% (15.6%; 75.8%)	
	III	205	50.1% (43.6%; 57.7%)	34.1% (27.9%; 41.6%)	27.7% (21.7%; 35.4%)	21.9% (16.2%; 29.7%)	21.2% (15.4%; 29.2%)	8.5% (3.2%; 22.1%)	
	IV	646	21.0% (18.0%; 24.4%)	10.3% (8.1%; 13.1%)	7.6% (5.6%; 10.3%)	4.2% (2.6%; 6.8%)	3.8% (2.3%; 6.4%)	-	
	X/NA	116	11.2% (6.7%; 18.9%)	4.4% (1.8%; 10.6%)	1.2% (0.3%; 5.6%)	1.3% (0.3%; 5.9%)	-	-	
	I	612	91.4% (88.8%; 94.0%)	82.4% (78.9%; 86.0%)	76.6% (72.5%; 80.9%)	73.0% (68.5%; 77.8%)	72.0% (67.2%; 77.1%)	64.1% (55.8%; 73.7%)	
	II	235	71.5% (65.6%; 77.9%)	57.7% (51.1%; 65.1%)	48.3% (41.3%; 56.5%)	43.5% (36.3%; 52.2%)	43.6% (35.8%; 53.0%)	34.8% (23.2%; 52.1%)	
	III	594	56.5% (52.5%; 60.8%)	38.6% (34.7%; 43.0%)	32.1% (28.2%; 36.6%)	29.3% (25.4%; 33.9%)	24.7% (20.5%; 29.6%)	20.4% (15.3%; 27.1%)	
	IV	1,399	24.6% (22.4%; 27.0%)	14.1% (12.3%; 16.1%)	10.7% (9.1%; 12.6%)	8.4% (6.9%; 10.3%)	7.4% (5.9%; 9.3%)	4.3% (2.6%; 7.1%)	
	X/NA	252	33.2% (27.8%; 39.8%)	24.8% (19.7%; 31.1%)	20.3% (15.5%; 26.5%)	17.3% (12.7%; 23.5%)	15.7% (11.1%; 22.1%)	13.7% (7.9%; 23.6%)	
	I	2,139	82.6% (80.7%; 84.5%)	66.6% (64.2%; 69.0%)	55.0% (52.4%; 57.8%)	45.9% (42.9%; 49.1%)	39.3% (36.1%; 42.9%)	18.1% (11.2%; 29.3%)	
Other	II	442	60.6% (55.8%; 65.9%)	41.7% (36.7%; 47.4%)	29.5% (24.6%; 35.5%)	24.0% (19.1%; 30.2%)	22.8% (17.5%; 29.6%)	13.1% (6.7%; 25.8%)	
	III	795	34.6% (31.3%; 38.3%)	19.7% (16.8%; 23.1%)	13.3% (10.7%; 16.5%)	10.5% (8.0%; 13.9%)	8.0% (5.6%; 11.3%)	6.1% (2.6%; 14.3%)	
	IV	1,712	10.9% (9.4%; 12.5%)	5.2% (4.1%; 6.5%)	2.7% (1.9%; 3.9%)	2.4% (1.6%; 3.6%)	1.6% (0.9%; 2.8%)	0.8% (0.3%; 2.6%)	
	X/NA	507	53.0% (48.5%; 57.8%)	39.8% (35.3%; 44.9%)	36.1% (31.4%; 41.6%)	31.0% (26.2%; 36.7%)	25.8% (20.9%; 31.8%)	10.0% (3.2%; 30.6%)	
	Females								
SCLC	I	169	84.7% (79.2%; 90.6%)	63.3% (56.1%; 71.4%)	51.3% (43.7%; 60.1%)	42.8% (35.1%; 52.1%)	40.3% (32.5%; 50.0%)	34.8% (25.5%; 47.4%)	
	II	147	74.5% (67.6%; 82.1%)	54.2% (46.4%; 63.4%)	46.7% (38.7%; 56.4%)	39.3% (31.0%; 49.7%)	34.0% (25.6%; 45.2%)	12.6% (4.6%; 35.0%)	
	III	1,079	63.8% (60.9%; 66.8%)	38.8% (35.9%; 41.9%)	28.2% (25.5%; 31.2%)	22.4% (19.8%; 25.3%)	20.4% (17.9%; 23.4%)	11.9% (8.9%; 16.0%)	
	IV	2,750	30.0% (28.3%; 31.8%)	11.6% (10.5%; 12.9%)	6.8% (5.8%; 7.9%)	4.9% (4.1%; 6.0%)	3.9% (3.1%; 4.9%)	2.5% (1.7%; 3.6%)	
	X/NA	366	34.0% (29.4%; 39.2%)	18.1% (14.5%; 22.6%)	13.0% (9.9%; 17.1%)	11.2% (8.2%; 15.3%)	9.0% (6.3%; 12.9%)	3.7% (1.8%; 7.9%)	
NSCLC	I	5,244	95.5% (94.9%; 96.2%)	90.3% (89.3%; 91.2%)	85.4% (84.2%; 86.6%)	82.0% (80.6%; 83.3%)	77.8% (76.3%; 79.4%)	64.0% (60.6%; 67.6%)	
	II	1,754	85.8% (84.1%; 87.6%)	74.7% (72.5%; 76.9%)	68.5% (66.1%; 71.0%)	62.5% (59.9%; 65.2%)	56.2% (53.3%; 59.3%)	35.5% (28.0%; 45.0%)	
	III	4,091	69.5% (68.1%; 71.0%)	52.5% (50.9%; 54.1%)	43.4% (41.8%; 45.0%)	38.0% (36.4%; 39.8%)	33.9% (32.2%; 35.7%)	21.7% (19.3%; 24.3%)	
	IV	10,616	42.9% (42.0%; 43.9%)	27.6% (26.8%; 28.5%)	20.2% (19.4%; 21.0%)	16.1% (15.4%; 17.0%)	13.6% (12.8%; 14.4%)	7.1% (6.1%; 8.3%)	

Type	Stage	N at risk	Net Survival Probability, 2013-2022							
			1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)		
SCC	X/NA	1,157	42.6% (39.8%; 45.6%)	31.1% (28.5%; 34.0%)	25.0% (22.4%; 27.8%)	22.0% (19.5%; 24.8%)	20.9% (18.4%; 23.8%)	13.8% (10.5%; 18.0%)		
	I	960	91.6% (89.7%; 93.6%)	81.4% (78.7%; 84.1%)	72.6% (69.4%; 75.9%)	66.9% (63.3%; 70.6%)	60.1% (56.2%; 64.2%)	38.0% (31.9%; 45.3%)		
	II	471	80.2% (76.5%; 84.0%)	65.7% (61.3%; 70.4%)	58.4% (53.7%; 63.6%)	53.0% (48.0%; 58.5%)	46.0% (40.7%; 52.0%)	29.7% (21.1%; 41.7%)		
	III	1,212	59.3% (56.5%; 62.2%)	39.3% (36.6%; 42.3%)	30.2% (27.5%; 33.1%)	27.0% (24.4%; 29.9%)	23.8% (21.2%; 26.8%)	14.7% (11.4%; 19.0%)		
	IV	1,333	34.7% (32.2%; 37.4%)	19.1% (17.0%; 21.4%)	13.0% (11.1%; 15.1%)	10.3% (8.6%; 12.3%)	8.8% (7.2%; 10.9%)	5.0% (3.0%; 8.3%)		
ADC	X/NA	248	43.3% (37.4%; 50.0%)	29.7% (24.4%; 36.2%)	22.5% (17.6%; 28.8%)	19.5% (14.8%; 25.6%)	17.7% (13.1%; 23.7%)	10.3% (6.0%; 17.6%)		
	I	3,558	96.3% (95.6%; 97.1%)	91.6% (90.6%; 92.7%)	87.0% (85.7%; 88.4%)	83.8% (82.2%; 85.4%)	79.7% (77.8%; 81.6%)	65.8% (61.5%; 70.3%)		
	II	1,082	87.8% (85.8%; 89.9%)	78.2% (75.6%; 80.9%)	72.3% (69.3%; 75.3%)	65.8% (62.5%; 69.3%)	58.6% (54.9%; 62.5%)	35.5% (25.4%; 49.7%)		
	III	2,498	75.2% (73.5%; 77.0%)	59.7% (57.7%; 61.7%)	50.2% (48.2%; 52.4%)	43.5% (41.3%; 45.8%)	38.4% (36.2%; 40.8%)	25.1% (22.0%; 28.7%)		
	IV	8,311	45.7% (44.6%; 46.8%)	30.1% (29.1%; 31.1%)	22.0% (21.0%; 22.9%)	17.5% (16.6%; 18.4%)	14.5% (13.6%; 15.5%)	7.4% (6.2%; 8.8%)		
LCC	X/NA	740	43.1% (39.6%; 46.9%)	30.7% (27.4%; 34.4%)	24.2% (21.1%; 27.7%)	20.9% (17.9%; 24.5%)	19.9% (16.8%; 23.6%)	11.1% (7.1%; 17.5%)		
	I	48	N<50	N<50	N<50	N<50	N<50	N<50		
	II	30	N<50	N<50	N<50	N<50	N<50	N<50		
	III	90	63.3% (53.9%; 74.4%)	46.6% (36.8%; 58.8%)	38.8% (29.4%; 51.3%)	35.3% (25.8%; 48.3%)	35.6% (26.0%; 48.6%)	19.8% (9.1%; 43.3%)		
	IV	277	22.0% (17.6%; 27.5%)	11.9% (8.6%; 16.6%)	8.5% (5.6%; 12.9%)	8.6% (5.7%; 13.0%)	8.7% (5.7%; 13.1%)	-		
Other NSCLC	X/NA	43	N<50	N<50	N<50	N<50	N<50	N<50		
	I	742	98.0% (96.7%; 99.3%)	96.3% (94.4%; 98.2%)	94.8% (92.5%; 97.2%)	93.2% (90.4%; 96.1%)	92.0% (88.7%; 95.5%)	90.1% (81.6%; 99.4%)		
	II	175	89.3% (84.5%; 94.3%)	79.2% (72.8%; 86.0%)	75.3% (68.3%; 83.0%)	71.5% (63.8%; 80.2%)	73.6% (65.7%; 82.6%)	60.4% (46.2%; 78.9%)		
	III	293	64.9% (59.5%; 70.7%)	47.9% (42.3%; 54.2%)	41.0% (35.4%; 47.6%)	38.7% (32.9%; 45.6%)	37.5% (31.4%; 44.7%)	21.9% (14.4%; 33.3%)		
	IV	700	34.1% (30.7%; 37.8%)	21.3% (18.4%; 24.7%)	17.6% (14.9%; 20.8%)	14.8% (12.2%; 17.9%)	13.4% (10.9%; 16.6%)	8.1% (5.1%; 12.9%)		
Other	X/NA	127	44.8% (36.9%; 54.6%)	38.8% (31.0%; 48.6%)	35.4% (27.7%; 45.4%)	32.8% (25.0%; 43.0%)	33.3% (25.4%; 43.6%)	33.9% (24.6%; 46.6%)		
	I	1,264	84.9% (82.7%; 87.1%)	73.0% (70.2%; 75.8%)	63.1% (59.9%; 66.5%)	54.9% (51.3%; 58.8%)	49.9% (46.0%; 54.1%)	28.8% (22.0%; 37.8%)		
	II	197	60.8% (53.9%; 68.5%)	45.5% (38.3%; 54.0%)	36.4% (29.0%; 45.6%)	29.1% (21.4%; 39.6%)	30.1% (21.7%; 41.7%)	25.5% (12.9%; 50.6%)		
	III	330	36.9% (31.8%; 42.8%)	22.3% (17.9%; 27.9%)	15.4% (11.5%; 20.7%)	14.3% (10.3%; 19.8%)	9.6% (6.2%; 14.8%)	5.9% (2.3%; 15.2%)		
	IV	748	15.5% (13.0%; 18.4%)	10.2% (8.1%; 12.9%)	9.0% (6.8%; 11.8%)	9.0% (6.7%; 12.1%)	10.0% (7.3%; 13.5%)	1.5% (0.2%; 9.8%)		

Net Survival Probability, 2013-2022								
Type	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	X/NA	303	62.0% (56.5%; 68.0%)	52.4% (46.6%; 59.0%)	49.0% (42.9%; 56.0%)	44.8% (38.2%; 52.6%)	42.1% (35.1%; 50.6%)	17.5% (7.1%; 43.2%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

5. CANCER SURVIVAL TRENDS



5.1. Lung Cancer Survival Trends: By stage

5.1.1. Lung Cancer Survival Trends: Stage, by sex, the number at risk and net survival probabilities over the 2008-2022 period

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2008-2012	I	4,103	84.3% (83.1%; 85.6%)	63.4% (61.7%; 65.1%)	51.6% (49.8%; 53.6%)	1,804	91.7% (90.3%; 93.1%)	76.4% (74.2%; 78.6%)	67.0% (64.5%; 69.6%)
	II	2,096	69.0% (66.9%; 71.1%)	43.5% (41.3%; 45.9%)	34.5% (32.3%; 37.0%)	665	77.8% (74.6%; 81.1%)	53.8% (49.9%; 57.9%)	46.0% (42.0%; 50.3%)
	III	5,843	53.2% (51.9%; 54.6%)	20.0% (19.0%; 21.2%)	13.0% (12.1%; 14.0%)	2,017	59.0% (56.8%; 61.2%)	27.6% (25.6%; 29.7%)	20.3% (18.6%; 22.3%)
	IV	10,623	25.3% (24.5%; 26.2%)	4.6% (4.2%; 5.0%)	2.3% (2.0%; 2.7%)	4,244	33.4% (32.0%; 34.9%)	8.5% (7.7%; 9.4%)	4.8% (4.2%; 5.6%)
	X/NA	5,335	31.5% (30.2%; 32.8%)	12.5% (11.5%; 13.4%)	8.8% (8.0%; 9.7%)	2,086	39.0% (36.9%; 41.2%)	18.0% (16.3%; 19.8%)	13.6% (12.1%; 15.3%)
2013-2017	I	4,779	87.3% (86.2%; 88.3%)	67.8% (66.2%; 69.4%)	57.0% (55.2%; 58.8%)	2,659	93.5% (92.5%; 94.6%)	81.0% (79.3%; 82.8%)	72.3% (70.2%; 74.4%)
	II	2,342	74.4% (72.6%; 76.4%)	48.5% (46.3%; 50.8%)	38.2% (35.9%; 40.6%)	910	78.9% (76.2%; 81.7%)	59.8% (56.4%; 63.3%)	49.1% (45.6%; 52.9%)
	III	5,900	57.0% (55.7%; 58.4%)	26.4% (25.2%; 27.6%)	18.5% (17.4%; 19.6%)	2,476	63.9% (62.0%; 65.9%)	35.2% (33.3%; 37.2%)	26.3% (24.5%; 28.2%)
	IV	12,577	25.5% (24.7%; 26.3%)	7.4% (6.9%; 7.9%)	4.5% (4.1%; 4.9%)	6,140	35.0% (33.8%; 36.2%)	13.1% (12.2%; 14.0%)	8.7% (8.0%; 9.4%)
	X/NA	2,633	32.5% (30.7%; 34.4%)	14.5% (13.1%; 16.0%)	8.5% (7.4%; 9.9%)	1,215	43.6% (40.8%; 46.5%)	25.2% (22.8%; 28.0%)	20.3% (17.9%; 23.0%)
2018-2022	I	5,738	90.8% (89.9%; 91.7%)	72.9% (71.4%; 74.4%)	60.3% (58.2%; 62.5%)	4,025	93.2% (92.3%; 94.1%)	80.1% (78.5%; 81.7%)	71.3% (69.0%; 73.6%)
	II	2,196	81.1% (79.3%; 82.9%)	58.0% (55.6%; 60.6%)	46.4% (43.3%; 49.7%)	1,187	85.6% (83.4%; 87.7%)	67.3% (64.2%; 70.6%)	54.5% (50.3%; 59.1%)
	III	5,669	63.5% (62.2%; 64.8%)	34.4% (33.0%; 35.9%)	25.6% (24.0%; 27.3%)	3,021	68.5% (66.8%; 70.3%)	41.7% (39.8%; 43.8%)	33.6% (31.4%; 36.0%)
	IV	13,466	33.4% (32.6%; 34.3%)	13.5% (12.9%; 14.2%)	8.6% (7.9%; 9.4%)	7,967	42.0% (40.9%; 43.1%)	20.2% (19.2%; 21.2%)	13.9% (12.9%; 15.0%)

Period	Stage	Males			Females				
		Net Survival Probability			Net Survival Probability				
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	X/NA	1,071	37.9% (35.0%; 41.0%)	22.4% (19.7%; 25.5%)	18.3% (15.1%; 22.1%)	612	45.2% (41.3%; 49.4%)	29.6% (25.8%; 33.9%)	27.0% (22.7%; 32.1%)

6. CANCER MORTALITY



6.1. Lung Cancer Mortality: By region, 2021

6.1.1. Lung Cancer Mortality*: Region, by sex, the number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Males																						
Belgium	0	0	0	0	1	1	2	4	13	38	98	202	443	592	689	646	538	368	147	16	3,798	74.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.5]	[1.1]	[3.5]	[10.0]	[24.6]	[50.1]	[122.0]	[193.2]	[260.0]	[370.8]	[411.8]	[473.7]	[523.6]	[293.4]	[66.9]	(71.6; 76.4)
Brussels	0	0	0	0	1	1	1	0	0	4	7	20	39	33	47	41	30	16	9	0	249	68.6
	[0.0]	[0.0]	[0.0]	[0.0]	[2.6]	[2.0]	[1.9]	[0.0]	[0.0]	[9.2]	[17.5]	[58.6]	[142.7]	[158.8]	[281.4]	[356.6]	[354.9]	[316.6]	[413.8]	[0.0]	[41.6]	(59.9; 77.3)
Flanders	0	0	0	0	0	0	0	2	5	20	48	86	229	317	437	409	349	231	87	10	2,230	69.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.0]	[2.3]	[9.3]	[20.5]	[35.2]	[103.7]	[168.8]	[269.9]	[358.2]	[404.6]	[446.8]	[474.8]	[279.3]	[67.7]	(66.2; 72.0)
Wallonia	0	0	0	0	0	0	1	2	8	14	43	96	175	242	205	196	159	121	51	6	1,319	85.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[1.8]	[7.0]	[11.4]	[34.7]	[76.7]	[152.4]	[247.3]	[237.2]	[403.9]	[442.3]	[577.9]	[673.1]	[426.7]	[73.9]	(80.9; 90.3)
Females																						
Belgium	0	0	0	0	0	0	2	4	13	26	66	132	240	337	347	298	228	143	71	11	1,918	30.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.1]	[3.5]	[7.0]	[17.0]	[33.0]	[64.6]	[103.3]	[117.1]	[139.7]	[123.2]	[105.8]	[107.1]	[57.2]	[32.8]	(29.4; 32.2)
Brussels	0	0	0	0	0	0	0	0	1	3	4	9	21	24	20	25	19	9	3	1	139	28.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.2]	[7.5]	[10.8]	[26.9]	[70.6]	[97.9]	[92.7]	[153.8]	[138.7]	[88.6]	[52.3]	[51.1]	[22.4]	(24.1; 33.8)
Flanders	0	0	0	0	0	0	1	3	4	11	34	79	120	194	189	169	138	70	43	5	1,060	28.3

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Wallonia	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.4]	[1.9]	[5.2]	[15.0]	[33.0]	[54.4]	[100.5]	[108.6]	[126.8]	[118.8]	[82.4]	[107.2]	[44.5]	[31.6]	(26.5; 30.0)
	0	0	0	0	0	0	1	1	8	12	28	44	99	119	138	104	71	64	25	5	719	36.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.9]	[6.9]	[9.8]	[22.6]	[34.5]	[81.8]	[109.5]	[136.9]	[163.2]	[128.7]	[159.8]	[122.4]	[82.8]	[38.6]	(33.5; 38.8)

7. CANCER MORTALITY TRENDS



7.1. Lung Cancer Mortality Trends: By Region

7.1.1. Lung Cancer Mortality* Trends: Males, by region, the number of cancer deaths, crude and age-standardised mortality rates over the 2004-2021 period, including average annual percentage change

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period		
Belgium	N	4,836	5,036	5,003	4,904	5,008	4,902	4,960	4,868	4,577	4,595	4,601	4,332	4,375	3,969	3,939	3,841	3,673	3,798				
	CR	95.1	98.5	97.3	94.6	95.9	93.0	93.4	90.6	84.5	84.4	84.0	78.7	79.0	71.3	70.4	68.2	64.9	66.9				
	ESR2013	125.9	129.6	125.3	120.6	121.1	115.8	115.4	111.6	102.7	101.2	99.7	92.3	92.1	81.5	80.4	77.1	72.4	74.0	-3.5 (-3.7; -3.2)	2004-2021		
																					-1.9 (-2.8; -1.0)	2004-2010	
																					-4.1 (-5.3; -3.0)	2011-2014	
																					-4.4 (-5.1; -3.7)	2015-2021	
Brussels	N	358	366	353	310	348	332	373	324	301	313	306	281	286	280	236	267	248	249				
	CR	74.5	75.7	72.1	62.4	68.9	64.3	70.8	59.7	54.4	55.7	54.0	49.1	49.3	48.1	40.2	45.1	41.5	41.6				
	ESR2013	111.4	115.8	108.5	95.5	106.8	97.9	113.5	96.5	88.5	90.0	88.1	80.7	81.7	79.5	67.1	73.5	68.5	68.6	-3.1 (-3.3; -2.8)	2004-2021		
Flanders	N	2,836	3,002	2,982	2,990	2,998	2,917	2,948	2,955	2,715	2,725	2,750	2,559	2,599	2,264	2,339	2,274	2,183	2,230				
	CR	95.6	100.7	99.5	99.1	98.6	95.2	95.5	94.9	86.6	86.5	86.9	80.4	81.2	70.3	72.2	69.8	66.5	67.7				
	ESR2013	123.3	127.3	122.9	120.4	118.7	113.2	111.5	109.7	98.8	97.2	96.4	87.7	87.7	74.4	76.3	73.1	68.6	69.1	-3.1 (-3.7; -2.6)	2004-2021		
																					-2.4 (-3.2; -1.6)	2004-2011	
																						-4.8 (-5.3; -4.2)	2012-2021
Wallonia	N	1,642	1,668	1,668	1,604	1,662	1,653	1,639	1,589	1,561	1,557	1,545	1,492	1,490	1,425	1,364	1,300	1,242	1,319				

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period	
CR	100.1	101.2	100.7	96.2	99.0	97.9	96.4	92.7	90.5	89.8	88.7	85.3	84.8	80.8	77.1	73.2	69.7	73.9			
ESR2013	135.1	138.2	134.3	127.7	129.5	125.4	123.2	118.9	114.1	111.4	108.6	104.0	103.1	96.5	91.3	86.0	80.4	85.6	-3.8 (-4.1; -3.5)	2004-2021	
																			-2.1 (-2.7; -1.5)	2004-2012	
																				-3.9 (-4.4; -3.4)	2013-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Lung Cancer Mortality* Trends: Females, by region, the number of cancer deaths, crude and age-standardised mortality rates over the 2004-2021 period, including average annual percentage change

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period	
Belgium	N	1,282	1,378	1,459	1,499	1,572	1,562	1,753	1,842	1,729	1,885	1,922	1,936	1,950	1,834	1,913	2,008	1,994	1,918			
	CR	24.1	25.8	27.2	27.7	28.9	28.5	31.7	33.0	30.8	33.4	33.9	33.9	34.0	31.9	33.1	34.6	34.2	32.8			
	ESR2013	24.8	26.3	27.6	27.9	29.2	28.6	31.6	32.8	30.5	33.2	33.3	33.2	33.0	30.7	31.4	32.9	32.1	30.8	1.2 (0.9; 1.5)	2004-2021	
																					3.0 (2.4; 3.7)	2004-2013
																					-0.8 (-1.5; -0.1)	2014-2021
Brussels	N	180	159	179	177	161	171	158	180	165	182	169	176	182	165	145	178	153	139			
	CR	34.6	30.4	33.8	33.1	29.7	31.0	28.1	31.2	28.2	30.7	28.3	29.2	29.9	27.1	23.7	28.9	24.7	22.4			
	ESR2013	38.2	33.7	38.4	36.7	34.0	35.8	32.3	37.2	33.7	37.8	34.9	36.7	36.6	33.9	28.9	35.2	30.4	28.9	1.4 (1.1; 1.7)	2004-2021	
Flanders	N	620	717	774	789	825	800	923	1,002	888	992	1,016	1,031	1,047	978	1,016	1,118	1,137	1,060			
	CR	20.3	23.4	25.1	25.4	26.4	25.4	29.1	31.4	27.6	30.7	31.3	31.6	32.0	29.7	30.7	33.6	34.0	31.6			
	ESR2013	20.4	23.6	24.9	25.0	25.9	24.8	28.2	30.1	26.6	29.2	29.4	29.7	29.7	27.3	27.9	30.5	30.5	28.3	-1.0 (-1.7; -0.3)	2004-2021	
																				3.5 (2.3; 4.7)	2004-2012	
																					0.0 (-1.0; 1.1)	2013-2021
Wallonia	N	482	502	506	533	586	591	672	660	676	711	737	729	721	691	752	712	704	719			
	CR	27.7	28.7	28.8	30.1	33.0	33.1	37.4	36.4	37.1	38.9	40.2	39.6	39.1	37.3	40.6	38.3	37.8	38.6			
	ESR2013	29.1	29.4	29.5	30.7	34.0	33.6	37.5	36.8	36.9	39.1	39.9	38.8	37.9	36.1	38.6	36.7	35.6	36.2	1.6 (1.1; 2.1)	2004-2021	
																				3.8 (3.1; 4.4)	2004-2013	
																					-1.2 (-1.9; -0.6)	2014-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Agentschap Zorg en Gezondheid; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021).

Recommended reference: Cancer Fact Sheets 2022, Belgian Cancer Registry (BCR), 2024